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Abstract
Myelination is the key feature of evolution in the nervous system of vertebrates.
Myelin is the protrusion of glial cells. More specifically, "oligodendrocytes" in the
central nervous system (CNS), and "Schwann" cells in the peripheral nervous system
(PNS) form myelin membranes. Myelin remarkably, enhances the propagation of nerve
impulses. However, myelin restricts the access of extracellular metabolites to the axons.
A pathology called "demyelination" is associated with myelin. The myelin sheath is not
only an insulator, but it is itself metabolically active. In this study it is hypothesized that
the ratio of NAD(P)+/NAD(P)H and the glycolytic pathway of the myelin sheath is
maintained via trans-plasma membrane electron transport system (t-PMET).
The t-PMET contains various membrane associated oxidoreductases by which
cells oxidize intracellular electron donors at the expense of the extracellular acceptors. In
this research two members of the t-PMET system, cytochrome b5 reductase (CB5R) and
NAD(P)H: quinone oxidoreductase (NQO1), were identified through enzymatic assays
and immunodetection analysis.
The CB5R was detected in the myelin membrane via Western blotting as two
bands, one at 35kDa and the other at 33kDa, potentially representing the myristoylated
and non-myristoylated forms, respectively. The enzymatic activity was measured as an
NADH: cytochrome c reductase activity and it was inhibited by the sulfhydryl agent phydroxymercuribenzoic acid.
The NQO1, an important antioxidant enzyme of t-PMET, was investigated in the
myelin membrane through immunodetection and kinetic analysis. Western blot analysis
i

revealed a truncated form at ~13kDa in the myelin sheath. Furthermore, the associated
activities of menadione-mediated cytochrome c reductase, water soluble tetrazolium 1
(WST-1) reductase and DCPIP reductase activity were found insensitive to the potent
NQO1 inhibitor, dicoumarol.
Another facet of this research demonstrated the activity and enzyme expression
level in the spontaneously demyelinating ND4 mouse model. The activity of CB5R was
temporal; it increased with age, but fluctuated at earlier stages of life. Higher activity of
NADH: cytochrome c reductase, and a higher rate of superoxide production were
measured in the diseased myelin. The level of NQO1 also fluctuated over time. The
fluctuation in the expression level may suggest its role in myelinogenesis, aging and disease.
CB5R and NQO1, both, play important roles in decreasing oxidative stress by Coenzyme
Q reduction, detoxification of quinones and xenobiotics, and through one and two
electron reduction reactions.
Overall, this study reveals several putative components of t-PMET in the myelin
membrane and provides a comprehensive insight into the activity of oxidoreductases
catalyzing one and two electron transfer reduction reactions and their expression level in
health and disease. The healthy and diseased myelin comparison will aid in deciphering
the role of the identified proteins in the myelin energetics and the pathologies related to
these enzymes.
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Chapter 1
Introduction
The major focus of this thesis is the investigation of a trans-plasma membrane
electron transport system (t-PMET) in the myelin membrane. An introduction to t-PMET
alongside its vital components and their functions is described in this chapter. Different
theories regarding myelin energetics are also presented. A hypothesis regarding myelin
energetics is established which states that the t-PMET is assisting myelin membrane in
maintaining the pyridine nucleotides pool. Lastly, the organization of this dissertation is
given.

1.1 The Central Nervous System
Cells need energy to sustain life which they obtain from food. Mainly, the
oxidation of food takes place in mitochondria, but starts in cytoplasm. Every cell type
has different energy requirements according to its structure and function [1]. Cells, in
particular skeletal muscles and neurons, need more energy than other cell types because
of muscle movement and propagation of nerve impulses.
The nervous system is predisposed for all biological processes happening in the
body and their communication with other body parts. The nervous system is divided into
two distinct parts, the central nervous system (CNS) and the peripheral nervous system
(PNS). The CNS, comprised of the brain and spinal cord, is believed to be the centre of
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all biological processing. Alternatively, the PNS incorporates nerves in the body and
plays a key role in reacting to stimulus transmitted by CNS [2].
Neurons are specialized cells in the nervous system that are capable of integrating
thousands of inputs into a single output, known as the action potential [3]. The neuronal
functional features such as the propagation of action potential and transportation of
enzymes, make them energetically expensive. For instance, the mammalian brain is 2%
of the total body weight but consumes 20% of the energy produced by the body [3]. To
reduce this energy requirement, the brain is divided into two parts; grey matter which
utilizes 1-1.6 µmol/g/min glucose, and white matter which utilizes 0.3-0.4 µmol/g/min
glucose [4]. The difference in the energy requirements can be explained on two levels.
Firstly, the neurons in grey matter have a high glucose requirement due to synapse
formation. Secondly, neurons in the white matter are ensheathed with a specialized lipidrich structure called "myelin" which encapsulates the neurons and conserves the energy
[5, 6]. Zalc et al. defined the myelin and its function altogether in a very concise manner:
“Myelin is hypothesized to enable a large body size by maintaining timely
communication between distant parts and to enhance precision in event
timing by reducing the absolute temporal variability in communication
between two points. These advantages are derived from the enhanced speed
of nerve impulse conduction that myelinated fibre enjoys relative to
unmyelinated ones of the same diameter" [7].
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1.2 Myelin-Structure and Function:
Myelin is formed from the extended protrusions of the oligodendrocyte cells
(OLs) in CNS, and the Schwann cells (SCs) in the PNS. OLs can myelinate multiple
axons and form approximately 40 or more distinct layers of myelin membrane. OLs and
SCs wrap their cytoplasmic extensions or processes around the axon to form concentric
layers of wrapped plasma membrane (see Fig 1.1) [8].
Myelin can be different in composition and function, depending whether it
originated from OLs and SCs. However, all myelin sheaths have a high lipid to protein
ratio. Myelin is composed of 70-80% lipid and almost 15-30% protein by dry weight. The
lipid content ratio is in the order of 2:2:1:1 of cholesterol, phospholipid, galactolipid, and
plasmalogens [7].

Fig1.1: The wrapping of the oligodendrocytes around axon. OLs cytoplasm is
compacted to form a dense structure. In the CNS, one oligodendrocyte can myelinate more than
one axon. Adapted from reference [7].
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1.2.1: Major Proteins in the Myelin Membrane:
The major protein in myelin is proteolipid protein (PLP) which is approximately
30-45% of the total protein mass. The PLP is involved in septin and sirtuins shuttling as
well as in transportation, strengthening and maintenance of myelin membrane [9]. It is
believed that PLP mutation is responsible for several neurological disorders, as a result of
the decreased axonal transportation [9]. The second most abundant protein is myelin
basic protein (MBP) which comprises of almost 15-25% of the total protein content. The
major role of MBP is to provide compaction to myelin sheath. The third most abundant
protein is 2´, 3´-cyclic nucleotide 3´-phosphodiesterase (CNP) that represents 5-15% of
the total protein content present in the myelin. The CNP is involved in RNA binding to
tubulin. The remaining 5-15% portion comprises of oligodendrocyte glycoprotein (MOG)
and myelin associated glycoprotein (MAG), and more than 1200 different kinds of
proteins [10, 11].
1.2.2: Advantages and Disadvantages of Myelin:

Communication is an issue due to large body size of gnathostomes where
millisecond precision is required. The evolution of myelin membrane solved this
problem. Some noticeable advantages of the myelin membrane are listed below:
•

The evolution of myelin reduces the energy requirement for neuronal
communication and boosts the speed of impulse propagation. Non-myelinated
axons use considerably more energy per unit length of neuron than myelinated
ones [12].
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•

Myelin gives the integrity to neurons and long term survival of neuron is made
possible by myelin membrane [12].

•

Myelin physically protects the CNS from autoimmune attack. It provides the
protection against CD8+and CD4+ activated T-cells [13].
However, a nearly completely insulated axon could be a double-edge-sword, as it

restricts the access of extracellular metabolites to the axon [12]. Furthermore, the energy
required in making myelin is greater than the energy conserved by myelin [12]. The
following key questions are the most important aspects in myelinated neuron energetics
and are the focus of research for last few decades:
•

Why and how OLs and SCs cells make myelin?

•

How do neuronal cells meet their energy requirements in the presence of myelin?

1.3: CNS Energetic Theories
Several theories are put forth to established the mechanism of interaction among
neurons, OLs, astrocytes, and flow of metabolites into and out of the myelin sheath.
1.3.1: Neuron-Oligodendrocyte-Astrocyte (NOA) Interaction Theory

According to NOA theory, glucose from blood capillary is taken up by neurons,
astrocytes, and oligodendrocytes (see Fig 1.2) [4]. This glucose is immediately
metabolized into pyruvate through glycolysis. Pyruvate is converted into lactate, and this
lactate can be absorbed by the cells with lower lactate concentration. Then the lactate is
metabolized into alanine or acetyl CoA which can enter into the TCA cycle [14].
Aspartate is converted into N-acetyl aspartate (NAA) in the neurons. Acetyl CoA is
5

necessary for this conversion. This NAA is transported into the oligodendrocytes where it
is converted back into aspartate and acetate. It is believed that acetate is extensively used
in myelin lipid synthesis [4]. According to this theory, the shuttling of metabolites
between the astrocytes, neurons, and oligodendrocytes is essential.

Fig 1.2: Schematic overview of NOA theory. The metabolic interaction between neuronoligodendrocyte-astrocyte (NOA). Adapted from reference [4].

1.3.2: Nave Hypothetical Model

Klaus Nave and colleagues proposed a structural model to elaborate the transfer
of glucose and its further processing in encapsulated neurons [15]. The hypothetical
architecture is depicted in Fig 1.3.
It is believed that OLs and astrocytes are coupled together and assist neurons for
energy production. Glucose is transported through glucose transporter protein 1 (GLUT
1) into the OLs and through connexin protein from astrocytes. Initially the glucose
6

undergoes oxidation in mature OLs, and the end glycolytic product, pyruvate, is
converted into lactate.

Fig 1.3: The hypothetical energy production model of myelinated axons by Nave. In
this model, glucose is transported through glucose transporter protein (GLUT 1). From OLs, the
end product of glycolysis, lactate, is transported to the underlaying axon. Myelin sheath itself is
also capable of maintaining glycolytic activity. Lactate produced from both the OLs and myelin
membrane, enters into the axoplasm through MCT 2 where it enters into the TCA cycle for more
ATP production. Adapted from reference [15].

The lactate is essentially shuttled across the myelin membrane by a transporter
protein called monocarboxy transporter 1 (MCT-1). Through another transporter isoform
MCT-2, it enters into the axoplasm. The lactate is used as an initial metabolite for TCA
cycle. In axoplasm, the lactate is converted back to pyruvate which is utilized in the
mitochondria for ATP production [15, 16]. According to this theory, glucose is utilized in
the myelin sheath (OLs processes) where it undergoes the oxidation and the end product
of glycolysis, pyruvate or lactate, is transported to the axon.

1.4: Proposed Alternative Model
For elucidation of myelinated-neurons energetics, an alternative model with a
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myelin perspective is presented in the current research project. This model is not
mutually exclusive to the Nave model, but hypothesizes another compensatory
mechanism within myelin membrane.
It is hypothesized that to satisfy the energy requirement of myelin and to perform
housekeeping functions, some compensatory mechanism such as trans-plasma membrane
electron transport system (t-PMET) is assisting myelin membrane. Many components of
mammalian t-PMET are now been identified. These are apparently ubiquitous and almost
the same. The availability of a variety of substrates and inhibitors of t-PMET has made it
possible to characterize and identify the structure of t-PMET in different cell types.
Scientists have explored t-PMET in several cell types, but none have investigated its
presence in myelin membrane.
Therefore, in this current research, it is hypothesised that
•

The myelin membrane supports t-PMET through unidentified enzymes.

•

The minimal structure of t-PMET consists of oxidoreductase enzymes, an internal
electron donor and an external acceptor (see Fig 1.4).

O2

Q

NAD(P)H

O2●-

Substrateox Productred

Plasma
membrane

QH2

+
NAD(P)H NAD(P)

NAD(P)+

Fig 1.4: Possible redox activities in myelin t-PMET. The external acceptor (oxygen) is
reduced by the t-PMET enzyme and reducing equivalents are derived from the NAD(P)H.
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1.5: Trans-plasma Membrane Electron Transport System (tPMET)
Trans-plasma membrane electron transport (t-PMET), also called as plasma
membrane redox system (PMRS), was discovered in 1960, and emerged as an important
system for cells [17]. The t-PMET utilizes almost 10% of the total oxygen consumption
in the cells [10], and functions in almost every organism including yeast, plants, algae
and animals [17]. In this system, the extracellular oxidants are reduced by t-PMET
components at the expense of intracellular reducing agents. Some of the important
functions associated with t-PMET are cell growth and death, proton pumping, ion
channel activity, and antibody modification.

1.5.1 Types and Components of t-PMET:
The trans-plasma membrane electron transport system reduces the extracellular
oxidants by two ways. One way is without enzymatic involvement and is referred to as
shuttle based electron transfer. Second method is even more complex and is mediated
through enzymes. The current focus of research is on the enzyme-dependent system. A
proposed structure of various identified enzymes in a t-PMET system is shown in Fig 1.5.
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Fig1.5: Key components of t-PMET. Intracellular electrons provided by NADH or ascorbate,
flow outward to reduce extracellular acceptors (oxygen, ascorbate free radical (AFR), ferric or
cupric ions). Several enzymes contribute to t-PMET. Some of them are: voltage dependent
anionic channel (VDAC), duodenal cytochrome b (Dcyt b), NAD(P)H oxidase (NOX) are transmembrane proteins, while disulfide thiol exchanger (ENOX) are terminal donor of electron to
oxygen and present at the outer surface of the membrane. Some important proteins such as
cytochrome b5 reductase (CB5R), NAD(P)H quinone oxidoreductase 1 (NQO1) are important
quinone reductases and present at the inner surface of plasma membrane. Co-enzyme Q (CoQ) is
an important antioxidant and acts as an intermediate electron carrier. Adapted from reference
[17].
1.5.1. A: Electron Donors

Intracellular reducing equivalents are derived either from NADH (reduced form
of nicotinamide adenine dinucleotide) or NADPH (reduced form of nicotinamide
dinucleotide phosphate). NADH is produced during catabolic processes such as
glycolysis, whereas NADPH is produced as a by-product in the pentose phosphate
pathway and is involved in the biosynthesis of fatty acids and cholesterol. The ratio of
NADH/NAD+ or NADPH/NADP+ is very important for the cells to perform different
biological functions as they directly affect the pH of the cell as well as redox state. In
steady state conditions, proton influx and efflux is maintained and no significant change
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in membrane potential is observed. But the accumulation of H+ in cytosol results in
hyperpolarization and membrane is depolarised when H+ is pumped out into the
extracellular space. This H+ is derived from the pool of NADH or NADPH [13].
Ascorbate (Asc) and flavonoids (vitamin E, quercertin) are intracellular substrates other
than NADH and NADPH. Their functions are also to protect the membrane from
extracellular stressors. Ascorbate promotes the t-PMET by two ways: A) By acting as an
electron donor in enzyme-mediated electron transport system, B) and acting as an
electron donor in non-enzymatic shuttle based transfer, where Asc directly acts as a
reducing agent and is oxidized to dehydroascorbate (DHA). This DHA is pumped across
the membrane where it is again converted to reduced form [18].
1.5.1.B: Electron Acceptors

The most important extracellular electron acceptor is oxygen. When it is fully
reduced, oxygen is converted to water, and when partially reduced, it can form reactive
oxygen species (ROS), such as superoxide radical (O2.-) or hydrogen peroxide (H2O2).
Superoxide radicals play a dual function, it not only act as a signal transducer but also
protects the cell. Other extracellular putative acceptors are ascorbate free radical (AFR),
ferric and copper ions [17].
1.5.1 C: Intermediate Electron Carriers

The most important intermediate electron carrier is co-enzyme Q (CoQ), also
known as ubiquinone. It is present between the lipid bilayer and links the inner surface
of the cell to the outer environment. CoQ can be transformed to ubisemiquinone and
ubiquinol (reduced quinone) by one and two electron reduction events, respectively.
Some other intermediate electron carriers are flavins and vitamin E.
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1.5.1.D: Oxidoreductases in t-PMET:

Enzymes are the important machinary in electron transfer. There are several
different kinds of enzymes with different localization in the plasma membrane. Some of
them are located at the outer surface like external NADH dependent oxidases (ENOX),
some are trans-membrane proteins such as NADH dependent oxidase (NOX), duodenal
cytochrome b (Dcytb), voltage dependent anionic channel (VDAC) and some are
localized on the inner surface of the plasma membrane like cytochrome b5 reductase
(CB5R) and NAD(P)H: quinone oxidoreductase 1 (NQO1).
The CB5R is present in plasma membrane, mitochondria and endoplasmic
reticulum. It is a monomeric flavin protein and the prosthetic group, flavin adenine
dinucleotide (FAD), is non-covalently bound. There are two known isoforms of this
enzyme; a membrane-bound and soluble form, with molecular weights of 35 and 32 kDa,
respectively. The major functions of CB5R involve fatty acid elongation, desaturation,
cholesterol synthesis and it also reduces the AFR back to Asc [19]. NQO1 is another
inner surface homodimeric flavo-protein with a molecular weight of ~30kDa for each
subunit. The enzyme is involved in cellular defence, stabilization of p53 gene and chemoprotection [20].
External NADH dependent oxidase (ENOX) is cell surface protein considered to
be the terminal electron donor to molecular oxygen. Three members of this family have
been reported: ENOX 1, ENOX 2 and ENOX3. They control the cell growth by disulfidethiol interchange activity [20].
Among trans-membrane proteins, NOX play a vital role in producing superoxide.
On the basis of structure, NOX are classified into three groups: a) NOX 1-4 b) NOX 5
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and c) DUOX 1-2. NOX 2 is well characterized in the t-PMET. NOX 1-4 are found in
epithelial, muscle cells, kidney lungs and spleen cells. They perform various functions
such as defence by invading the microbes through production of superoxide and ther are
considered to be the regulator of calcium in cells. DUOX 1-2 is mainly found in thyroid
gland [21]. Duodenal cytochrome b (Dcytb) is novel protein that is induced in response to
hypoxia and iron deficiency. Dcytb protein with a molecular weight of 33kDa plays a
crucial role in iron metabolism [22].
Voltage dependent anion channel (VDAC) is another integral membrane protein
with a molecular weight of ~30-35kDa. The channel's major function involves the
trafficking of metabolites between extracellular space and cytoplasm. Another vital
function of the channel is the release of apoptogenic proteins [23].

1.5.2: Functions of t-PMET:
Beside some general functions such as the trafficking of molecules, various
physiological roles are also associated with t-PMET. The plasma membrane has a
complex signalling system for regulating cellular metabolism and performing other vital
functions for the cells such as maintaining homeostasis, pH control, proton pumping and
antibody control.
Proton movement is one of the important functions of t-PMET. Proton movement
is carried out by the Na+/H+ anti-porter, which facilitates the movememt of the ions across
the membrane. Due to ion exchange through plasma membrane, the internal and external
pH gradient changes, which regulates cell volume sensing and apoptotic signaling [24].
Enzymes such as NOX2, NOX5 and DUOX are involved in sperm maturation and
fertilization. Furthermore, since mitochondrial function is often defective in
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spermatozoas, upregulation of t-PMET maintains the ratio of NAD+/NADH [23]. The
DUOX enzyme generates the hydrogen peroxide that not only helps the spermatozoa in
defence against xenobiotics but also helps the cells in developing a cross-linking of
envelope proteins, thus provides a physiological structure to avoid polyspermy [25] .
Another critical function of t-PMET is the maintenance of redox homeostasis.
Alteration of membrane redox potential leads to dramatic change in platelets function in
uremic patients. The deoxygenated erythrocytes, show decreased levels of NADPH and
glutathione reductase (GSH), and therefore showing the depletion of membrane thiol pool
and an increased oxidative stress. In this condition, t-PMET uses Asc as an electron
donor. A single hemodialysis event in uremic patients triggers two responses:

(1)

removal of toxic compounds, and (2) regulates t-PMET efficiently [26].
Loss or overstimulation of t-PMET leads to different pathologies. Apoptosis is a
process involved in cellular homeostasis and tissue development. The process must be
tightly regulated, since defective apoptotic progression has been implicated in several
diseases. For instance, excessive apoptosis causes hypotrophy, whereas an insufficient
amount results in uncontrolled cell proliferation, such as cancer. Inhibition of t-PMET
causes ROS generation, which in turn leads to a pro-oxidant environment at the plasma
membrane and promotes apoptosis [24, 27] . The potential involvement of t-PMET in cell
death is further suggested by the finding that NAD+/NADH and CoQ/CoQH2 ratios are
important modulators of neutral sphingomyelinase, which catalyzes the generation of
ceramide pathway from sphingomyelin, and allow the clustering of death receptors and
transmission of an efficient death signal into the cells [28].
Normal tissues derive most of their energy by metabolizing glucose to carbon
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dioxide and water through mitochondrial oxidative phosphorylation. Conversely, cancer
cells convert glucose to lactate irrespective of oxygen presence or absence. This
phenomenon, described by Warburg in the early 1900s (known as the ‘‘Warburg effect’’),
emphasizes that cancer cells rely less on mitochondrial activity than the normal cells. The
role of t-PMET in cancer biology relies on the observation that the metabolic changes
described above may perturb key redox couples, including the NAD(P)H/NAD(P)+ and
CoQH2/CoQ ratios, which play a crucial role in supporting cell survival, function, and
growth of fast proliferating cells. Cancer cells usually exhibit elevated level of t-PMET
[29]. It has been suggested that ENOX2 levels may be associated with the ability of
tumour cells to acquire an aggressive phenotype [30]. Some NOX isoforms have been
associated in early stages of carcinogenesis which implies the role of t-PMET in cancer
cells. Most anti-cancerous drugs target the t-PMET inhibition.
The t-PMET system has a role in cardiovascular diseases, including hypertension,
atherosclerosis, and vascular complications of diabetes. Hypertensive patients show
increased NOX-dependent superoxide production in vascular smooth muscle cells [31].
When ubiquinone-dependent electron transport is disrupted, t-PMET becomes a source of
ROS, triggering oxidative stress and apoptosis. This phenomenon has been proposed to
be one of the factors responsible for the onset of age-related pathologies. Therefore, tPMET system exerts a protective role by maintaining optimal levels of plasma
antioxidants [28].
Experimental evidence suggests that some superoxide generating NOX isoforms
may be involved in the clinical progression pathogenesis, as well as in several
neurodegenerative disorders. For instance, in the brain of Alzheimer's patients, membrane
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localization of p47phox (a NOX subunit) is increased, and at the same time, amyloid-β
peptides can enhance NOX activity. Consistently, knockdown of p22phox inhibits
amyloid-β peptide-induced neuronal apoptosis [32].

1.6 Thesis Organization
Due to complex anatomy of myelinated neurons, their energetics are difficult to
explain. Several theories have been put forth hitherto. In this research, a theory of tPMET association with myelin membrane is presented, and components of t-PMET were
identified in myelin membrane. This thesis is divided into two parts. First part (chapter 14) explores putative components of t-PMET in myelin membrane. Second part (chapter
5) compares identified components between healthy and diseased myelin.
Chapter 2: Chapter 2 of this thesis deals with objectives and rationale. Methodology to

achieve these objectives is also described in this chapter.
Chapter 3: CB5R is an enzyme present in plasma membrane electron transport system. In

this chapter, CB5R existence in myelin membrane is investigated.
Chapter 4: NAD(P)H: Quinone oxidoreductase 1 (NQO1) is another t-PMET enzyme

involved in defense against stress. This chapter deals with the investigation of NQO1 in
myelin membrane.
Chapter 5: A neurodegenerative disorder, multiple sclerosis, is introduced. A comparison

of previously identified enzymes activities is done with diseased myelin model.
Chapter 6: This chapter summarisies the dissertation with conclusions and also reveals

some future research directions.
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Chapter 2
Objectives, Approaches and
General Methodologies
This chapter describes the objectives and general methodologies of the current
research work. Different approaches for studying t-PMET such as the measurement of
reduction of artificial acceptors and superoxide production are described. The
immunodetection of proteins and enzyme kinetics are other important aspects discussed
in this chapter. Lastly, the impact and significance of current research work is elucidated.

2.1 Objectives
The t-PMET system allows the reduction of extracellular oxidants at the expense
of intracellular reducing equivalents. In this way, cells not only respond to change in the
redox microenvironment but also gain the ability to regulate their important housekeeping functions such as cell metabolism, proton pumping, ion channel activities, cell
growth and death [33]. The purpose of this research is to characterize the proteins and
enzymes that may be involved in t-PMET within the myelin membrane. A plethora of
research has been done on t-PMET system of endothelial, phagocytotic and erythrocytic
cells. However, researchers have not investigated the existence of t-PMET in myelin
membrane. Detailed studies of t-PMET are important as its existence not only plays a
key role in metabolism but it also has implication in various pathologies including
neurodegenerative disorders [17].
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The main objectives of this study are:
i.

To determine the enzyme redox activities in myelin membrane.

ii.

To establish the distribution and localization of each redox enzyme in different
myelin membrane microdomains.

iii.

To compare healthy myelin with "diseased" myelin in terms of
a) oxidoreductase activities,
b) enzyme protein expression level, and
c) production of superoxide.

2.2 Methods of Studying t-PMET
The study of a complex biological system is divided frequently into three stages.
First is the overall tissue structure determination (general structure of t-PMET is
depicted in Fig 1.5). Second, the individual components must be identified, which is
the paramount area of discussion in this research. The third stage is the determination
of juxtaposition of these components, and elucidation of their structural and functional
role with each other [34, 35]. Several methods are employed to study t-PMET [29, 3436]. Some of these methods are listed below;
i.

Measurement of reduction of an artificial or exogenous electron
acceptor

ii.

Measurement of disappearance of an electron donor

iii.

Measurement of oxygen consumption

iv.

Measurement of superoxide production
18

v.

Measurement of ubiquinone reduction

In this research project, components of t-PMET were characterized or identified
through measuring the reduction of the artificial acceptors, disappearance of an
electron donor, and superoxide production. These approaches are described below.

2.3 General Approaches to Measure Redox Activities
The t-PMET system includes oxidoreductase enzymes. These oxidoreductase
enzymes catalyze redox reactions; the transfer of electrons from one molecule to another
molecule. An objective of this research was to determine the redox activities in myelin
membrane which was accomplished through monitoring of electron transfer from
electron donor to electron acceptor. The general activity can be measured with NADH or
NADPH as an electron donor and an electron acceptor such as cytochrome c or
tetrazolium salt.
NADH + substrate (ox)

Enzyme

NAD+ + product (red)

(2.1)

The expression 2.1 illustrates the oxidoreductase reaction in which NADH in
reduced form donates two electrons (as a hydride) and reduces the oxidized substrate
(electron acceptor), produces the oxidized form of the electron donor, NAD+ and the
product. The electron transfer can be monitored spectrophotometrically at a specific
wavelength following the oxidation of NADH or the reduction of the substrate. When
NADH is monitored, a decrease in absorbance at 340nm is measured. As NADH
donates electrons, the concentration of NAD+ (oxidized form) increases, while
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concentration of NADH (reduced form) decreases. The electron donor NADH has an
characteristic absorption spectrum and a maximum absorption at 340nm.
Many oxidoreductase-catalyzed reactions are monitored with an artificial electron
acceptor (substrate). The selection of artificial electron acceptor is crucial. There should
be following characteristics in artificial acceptor [16]:
•

Artificial acceptor must have strong chromophore in oxidized or reduced form,
such as 2, 6-dichlorophenol indophenol (DCPIP).

•

Artificial acceptor should carry large multiple negative charge; for example,
ferricyanide.

•

Artificial acceptor or endogeneous substrate must have high molecular weight,
such as toluidine blue O or cytochrome c.
Due to high molecular weight and multiple negative charge, these substrate are

impermeable to the membrane. To investigate the enzyme activities in myelin, a system
was developed in which a sample of myelin membranes was reconstituted in a buffer (to
maintain the pH of the system, usually Tris buffer), with a suitable substrate such as
cytochrome c or dichlorophenolindophenol (DCPIP) (as final electron acceptor) and
NAD(P)H (as the electron donor).

2.4 General Approach to Measure Superoxide Production
NAD(P)H oxidase or NOX, which is characterized as a superoxide generating
enzyme, is another class of t-PMET enzymes. Superoxide plays a vital role in cellular
defense, signal transduction, angiogenesis, blood pressure regulation, and biosynthesis
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processes [37]. These enzymes use NAD(P)H as an internal electron donor and reduce
the external oxygen by an one electron reduction into superoxide. The superoxide is
spontaneously or enzymatically dismutased by superoxide dismutase (SOD) to hydrogen
peroxide and oxygen. Hydrogen peroxide also acts as a messenger molecule [17]. Several
methods are employed to detect superoxide production in cells. Some of them are:
i.

Detection of superoxide through lucigenin-derived chemiluminescence

ii.

Detection of superoxide through cytochrome c reduction

iii.

Detection of superoxide through WST-1 (water soluble tetrazolium generation 1)
reduction
In this research, any measurable quantity of superoxide was detected by WST-1.

Tetrazolium was reduced to formazan by superoxide which indicates the occurrence of a
redox reaction and presence of superoxide radical. Expression 2.2 illustrates the nonenzymatic reaction. The formazan production can be detected at 438nm with an
extinction co-efficient of 37mM-1 cm-1.
O2-. + WST-1

O2 + Formazan

(2.2)

2.4.1 Enzyme Kinetics
There are several advantages of enzyme assays including their low cost, reliability
and simple procedure. Besides these advantages, the most important advantage is the
ability to investigate or study the kinetics and inhibition study of the enzyme.
Enzyme kinetic study is the branch of science that deals with reactions that are
catalyzed by enzymes. This analysis provides useful parameters related to rate of
reaction. When enzyme (E) binds to a substrate (S), it forms an enzyme-substrate
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complex (ES). After sometime, this ES is regenerated to enzyme (E) and substrate is
changed into product (P). This enzyme catalytic mechanism is described in equation
below:
k1
E+S

k-1

ES

k2

E+P

(2.3)

In kinetic analysis the enzyme rate is measured for a series of concentrations of
the substrate, as shown in Fig 2.1

Fig 2.1: A typical Michaelis-Menten kinetics representation. Vmax represents the
enzyme maximum velocity while KM reprsents the substrate concentration at which
reaction attains its half maximum velocity. Taken from reference [38].

The mathematical modulation of Michaelis Menten model is described by the
equation 2.4, and is used to study the asymptotic reaction. This equation graphically
represents a hyperbola which is defined by two asymptotic parameters Vmax and KM.
𝑉=

𝑉𝑚𝑎𝑥 [𝑆]

(2.4)

𝐾𝑀 +[𝑆]

where
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Vmax = Maximum velocity of the reaction
[S] = Substrate concentration
KM = Michaelis constant or 1/2 Vmax
The Vmax represents the maximal enzyme reaction velocity, when the enzyme is
fully saturated with the substrate, and KM reflects the affinity of enzyme-substrate
interaction which is the substrate concentration to attain half maximum velocity.
The significance of Michaelis-Menten kinetics is that it provides the useful
information about the rate of reaction, mechanism, and the enzyme nature. If the kinetic
plot of an enzyme is similar to Fig 2.1, then the enzyme involves the single substrate. If
plot is different from Fig 2.1, such as sigmoidal, then the enzyme may involve two
substrates and may have ping-pong mechanism or could be allosteric in nature. Thus,
Michaelis Menten equation describes chemical as well as some physical aspects of the
enzyme.
The enzyme activity for oxidoreductases can be calculated following reduction of
acceptor or oxidation of donor. According to Beer's law as concentration of substrate
(chromophore in substrate) increases absorbance also increases. The general equation is
A = εlc

(2.5)

To monitor the enzyme activity, the change in absorbance of substrate over time
is plotted. Enzyme activity can be calculated from the slope of the plot and the Beer's law
relationship.
Activity = Slope x 60sec/min x 1/ ε (M-1 cm-1) x l(cm) x volume (L) x 106 µmol/mol
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where l = path length
ε = extinction coefficient
slope = ∆Abs/min

2.5 General Methodologies
Some common methodologies and techniques that were utilized throughout the
research project are discussed below.

2.5.1 Isolation of Myelin
Isolation of myelin from mouse brain was completed by the sucrose gradient
method [39]. The brains tissues were homogenized with a Douncer homogenizer on ice in
10.5% (w/v) sucrose prepared in TNE (25mM Tris buffer, pH 7.4, 150mM sodium
chloride and 5mM EDTA (ethylene diamine tetraacetic acid). The brain homogenate was
layered on top of 2mL 30% (w/v) sucrose solution. The mixture was centrifuged using
MLS-50 swinging bucket rotor at 35,000 rpm for one hour in the Optima Max
ultracentrifuge (Beckman Coulter). The white myelin layer was carefully removed at the
30% (w/v) sucrose solution interface. After centrifugation myelin was diluted by icechilled milli Q water in a 1:1 ratio. To pellet the myelin membranes, an additional
centrifugation at 35,000 rpm was performed for 30 minutes. The isolated myelin vesicles
were osmotically shocked by addition of ice-chilled milli Q water and incubated on ice
for 10 minutes, and followed by the subsequent centrifugation for 20 minutes at 22,300
rpm. The procedure of sucrose gradient separation and osmotic shock was repeated for
better separation. Myelin pellets were resuspended in ~500µl of myelin storage buffer
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[(500µl 2X TBS, 40 µl PIC (protease inhibitor cocktail), 20µl 100mM Na3VO4, 20µl
100mM phenylmethane sulfonylfluoride (PMSF), 20µl Phos STOP (phosphatase
inhibitor cocktail), 400µl water)]. After isolation, the concentration of myelin samples
was determined using microplate procedure of bicinchoninic acid (BCA) protein assay
(Pierce). All samples were read at 562 nm.
2.5.1(A) Myelin Detergent Fractionation

The myelin membrane consists of several microdomains but two microdomains,
the radial component and lipid rafts, have been previously described [40]. Lipid rafts are
region of plasma membrane rich in cholesterol and glycosphingolipids [40]. The
membrane phase in which cholesterol and sphingolipids are rich and tightly packed is
called the liquid ordered phase (L0). This compactness creates thick, less fluid and a more
ordered membrane structure. The proteins that are involved in signaling are mostly
partitioned into lipid raft region [40]. The radial component is the structure within the
compact myelin where closely associated cytoplasmic bilayer leaflets alternate with
closely associated exofacial bilayer leaflets and radiates as a bicycle wheel spoke [41].
Radial component mostly consists of tight junctions between membrane layers, whereas
the lipid rafts are a linear region within a membrane.
From most cells, lipid rafts can be isolated as detergent resistant membranes
(DRMs). A detergent fractionation method can be used to separate the lipid raft
microdomain from radial component in myelin. Hydrophobic proteins are difficult to
separate and identify, as they are often present in cholesterol-rich microdomains (lipid
rafts) of the membrane. Thus the procedure requires detergent for their purification.
Detergents are chemical compounds that have both hydrophobic and hydrophilic
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structure. The tails of detergent are essentially hydrophobic and the heads are
hydrophilic. There are three types of such detergents: ionic, non-ionic, and zwitterionic.
Zwitterionic

detergents

such

as

CHAPS,

(3-[(3-cholamidopropyl)

dimethylammonio]- 2-hydroxy-1 propanesulfonate), which have head groups with
both kind of charges can be used. The mechanism of action of these detergents is to
disrupt the lipid-lipid and lipid-protein interactions. Due to disruptive ability of these
detergents, they are considered even more efficient than non-ionic detergents.
CHAPS, at 1.5% (w/v), has been used efficiently to isolate the lipid raft components
from myelin membranes [42].
Being milder than ionic detergents, some non-ionic detergents are also
utilized in protein extraction from myelin membranes [43]. Uncharged hydrophilic
heads are the characteristic feature of non-ionic detergents such as triton X-100 (TX100) and Tween-20. TX-100 has been used to separate the radial component of
myelin sheath [44]. Sodium dodecyl sulfate (SDS), an anionic detergent, was not
used in fractionation procedure due to its denaturing ability.
The overall procedure of detergent fractionation with myelin membrane is
illustrated in Fig 2.2. Myelin (500µg) was added to 500µl of 2X Tris buffer saline (TBS;
50mM Tris/HCl pH 7.5, 280mM NaCl, 4mM EDTA) and 150µl of 1.5% (w/v) CHAPS
detergent, with the final volume adjusted to 1000µl with water [40]. Sample mixtures
were gently vortexed and subjected to 30 minute incubation on ice. Centrifugation at
5000xg for 10 minutes was done at 4ºC. Supernatant was removed and called the S1
fraction. Pellets were resuspended in 1mL of 3% (w/v) TX-100 solution and labeled as
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P1. A gentle shaking was required to dissolve the pellet. Incubation of the pellet solution
at room temperature was done for 30 minutes. The 2% (w/v) TX-100 was added and
centrifugation was completed at 14000xg at room temperature for 15 minutes. This
supernatant was labeled as S2 and the pellet was dissolved in 1mL of 3% (w/v) TX-100
solution and labeled as P2. If a specific protein is present in S1, it may be localized in
the lipid raft microdomain, whereas if it is present in P1 and/or P2 fraction, it may be
localized in radial component of the myelin membrane.

myelin (500 µg protein)
1.5% CHAPS, 4°C
5000xg

pellet P1

supernatant

S1

2% TX100, RT
14000xg

supernatant

pellet

S2

P2

Fig 2.2: Schematic of the myelin detergent fractionation procedure. CHAPS is
used to fractionate and isolate the lipid raft components from the myelin membrane,
whereas TX-100 is utilized to fractionate the radial component.

2.5.1(B) Myelin Delipidation

To remove excessive lipid content for efficient electrophoresis of protein, myelin
can be subjected to partial delipidation. Delipidation was achieved by treating the myelin
with ether and ethanol in a 2:1 ratio. The myelin membranes (250-1000µg) were thawed
on ice. The final volume was brought to 200µl by adding milli Q water. To the diluted
myelin, 500µl of ether:ethanol (2:1 ratio) was added for lipid removal. Incubation of the
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mixture was completed on ice for 10 minutes. Subsequently, centrifugation at 10,000xg
for 10 minutes was completed at 4°C. The supernatant fraction containing the lipids was
discarded. Pellets were partially air-dried, and then were dissolved in resuspension buffer
(10mM Tris-HCl, pH 8.0 and 1% SDS).
2.5.1 (C) Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis and Western
Blotting

Once the myelin fractions were sepa rated, 64µl of each fraction was added to
16µl of 5x sample loading buffer (0.5M Tris/HCl, pH 6.8, glycerol, 10% w/v SDS, 0.5%
(w/v) bromophenol blue). Samples with loading buffer were boiled for 5 minutes which
was used immediately or stored at -20°C after cooling for later usage.
The 12% and 14% resolving gels with 4% stacking gels (1mm, 8 x 7.3cm: MiniProtean, BioRad) were used for Western blot analysis. The 10X running buffer or
electrode buffer (25mM Tris/HCl, pH 8.3, 192mM glycine, 0.1% SDS) was diluted into
1:10 and ~500mL was utilized to run SDS-PAGE. Protein samples, either delipidated
myelin or detergent fraction, in the loading buffer were loaded along with protein MW
standards. Electric current was applied. For the first 20 minutes the applied voltage was
70V to facilitate the stacking of the proteins. After 20 minutes, the voltage was changed
from 70V to 120V for an additional 80-90 minutes. After 90 minutes or when the dye
front was out of the gel, the gel was disassembled and washed with transfer buffer
(25mM Tris-HCl, 192mM glycine, pH 8.3, 20% methanol) for 5 minutes. Protein
transfer onto the nitrocellulose membrane was accomplished by arranging the gel and
membrane in the following order; fiber pad, 2 pieces of filter paper, gel, nitrocellulose
membrane, 2 pieces of filter paper and at the very end fiber pad. Approximately 400-500
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mL of ice-cold transfer buffer was required to fill the tank along with an ice pack.
Current was set at 200mA for 2 hrs. After 2 hrs, the cassette was disassembled and
nitrocellulose membrane was subjected to further western blot analysis after drying. The
transfer of protein markers are indication of sucessful protein transfer.
For Western blot analysis, the membrane was blocked with 5% (w/v) milk
solution (2.0g skim milk powder in 40 mL 1XTTBS) for 2.5-3 hrs. All antibodies and
milk solutions were made in 1XTTBS solution by diluting 10XTTBS (247mM Tris, pH
7.6, 0.026M KCl, 0.137M NaCl, 0.5% (w/v) Tween-20) solution in 1:10. Two washings
of one and five minutes with 1X TTBS were followed the blocking step. Subsequently,
the membrane was incubated with primary antibody (concentration as provided by
antibody supplier) for 1-4 hrs or more. After incubating with primary antibody, the
membrane was washed once with 20mL 1XTTBS solution and for three more times each
for 5 minutes. The membrane was incubated with a secondary antibody for 30-45
minutes (concentration as provided by antibody supplier). Secondary antibody incubation
was followed by washing the membrane three times with 20mL 1XTTBS solution for 5
minutes. For imaging, the membrane was incubated with Super Signal West Femto
reagent (Pierce) for 5 minutes as outlined by the manufacturer. Imaging was acquired
immediately by a VersaDoc 4000 (Bio-Rad Ltd) system.

2.5.1 (D) Immunohistochemistry
Fluorescence microscopy images of myelin membrane proteins were acquired
with a CCD camera (binning mode) attached to a 300 Nikon epifluorescent microscope.
The oil immersion 100X objective was used in this study. Myelin samples were diluted
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into 1:1000 by volume and applied to the glass slide. The 10µl of diluted sample was
incubated with 40µl primary antibody at room temperature for 1hr. The dilution of
primary antibody was provided by the supplier and was prepared in PBS buffer (5mM
sodium phosphate, 137mM NaCl and 27mM KCl, pH 7.0). After incubation with the
primary antibody, samples were washed three times with PBS buffer and subsequently,
incubated with fluorescently tag secondary antibody for 30 minutes at room temperature.
The secondary antibodies were also prepared in PBS (secondary antibody dilution as
provided by the supplier). After washing with PBS, image was taken by 300 Nikon
epifluorescent microscope.

2.6 Research Significance
Myelin, a multilayered sheath, not only provides integrity and insulation to the
neurons but it is also metabolically active. It is still controversial that to meet its energy
requirements, myelin must either be self-sufficient (utilizing the t-PMET system) or
dependent on distal mitochondria. Over recent years, the theories of oligodendrocyte,
astrocyte, neuron and myelin interaction for myelin energetics have emerged [4, 12, 15].
In the current research, the theory of t-PMET association with myelin membrane for its
energy requirement is presented for the first time. This research project investigated the
association of t-PMET with myelin membrane. The identified component's activity and
expression level were measured in the demyelinated system. The role of t-PMET in
health and disease will further assist in deciphering the functions of these identified
enzymes and their role in demyelination.
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Chapter 3
Investigation of Cytochrome b5
Reductase in the Myelin Membrane
The central theme of this chapter is to investigate the presence of cytochrome b5
reductase (CB5R) in myelin membrane through its associated activity of NADH:
cytochrome c reductase. The kinetic parameters Vmax and KM were determined to
describe the reductase activity. Furthermore, para-hydroxymercuribenzoic acid (pHMB),
a potent inhibitor of CB5R was used. Western blot analysis and immunohistochemistry
were performed to confirm the presence of CB5R in myelin membrane. Lastly, detergent
fractions of myelin were assayed for comparing the enzyme activity and localization in
the membrane microdomains.

3.1 Introduction
Cytochrome b5 reductase (CB5R), is an NADH-dependent, FAD-containing
integral membrane protein [45]. The CB5R catalyzes two coupled, single electron
reductions of substrates such as Cb5 or CoQ. A pair of electrons, as hydride ion, from
NADH are transferred to the flavin ring of FAD, and then from the reduced form of FAD
these electrons are transferred one at a time to two molecules of Cb5. Overall, the
electrons are transferred from the two electron carrier (NADH) to the one electron carrier
(Cb5). The FAD can cycle from the fully reduced form of FADH- to the semiquinone and
then back to the fully oxidized form FAD. The catalytic mechanism is shown in Fig 3.1.
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Fig 3.1: Catalytic cycle of FAD in CB5R. The two electrons are transferred via hydride
transfer from NADH to the fully oxidized form of FAD to give the reduced form. One electron
from FADH- is transferred to the substrate (Cb5) or single electron acceptor to yield the neutral
blue semiquinone which is deprotonated to the anionic red semiquinone. A second electron is
transferred to another single electron acceptor. Figure taken from reference [46].

In humans, CB5R is encoded by four genes CB5R1, CB5R2, CB5R3 and
CB5R4. The isoform, CB5R3 has ubiquitous expression and is present in mitochondria,
nucleus, endoplasmic reticulum and plasma membrane. The CB5R3 is encoded by the
gene present on chromosome number 22 and this gene is 32 kb in length (with 9 exons
and 8 introns) [47]. Two isoforms of CB5R are known. One isoform is membrane-bound
with a molecular weight of ~35kDa, while second isoform is soluble with a molecular
weight of ~33kDa. The soluble form is mostly found in the erythrocytes [48]. The
difference in two forms lies in their N-termini. In membrane-bound form, the N-terminus
is myristoylated and hydrophobic. This hydrophobicity of the chain facilitates the enzyme
insertion into the membranes. The soluble form is produced by the alternate splicing of
membrane-bound form [48, 49].
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The X-ray crystallographic studies have resolved the enzyme fold and structure.
Overall, the enzyme consists of two functional lobes (Fig 3.2A). The prosthetic group,
FAD, binding site is present on N-terminus lobe. This FAD binding domain (Lys33His144, in the human sequence) consists of six antiparallel β-strands [36]. The NADH
binding site lies in the C-terminus lobe (Gly171- Phe300) and has an αβα motif. The Nterminus and C-terminus lobes of enzyme is linked by a small peptide, which is a short
random coil of 25 amino acids [36]. This short random coil acts as a hinge and is thought
to facilitate the efficient transfer of electron from NADH to FAD by holding their binding
sites in close proximity to one another (Fig 3.2B) [50].
B

A

Fig 3.2: Overall structure of human CB5R. Panel (A): FAD binding domain is in blue,
while NADH binding domain is in red. The linker domain is in green. Adopted from reference
[46]. Panel (B): Interface of NADH and FAD domains. Adapted from reference [53].

The distance between the FAD binding domain and NADH binding domain is
~11Å [36]. How is efficient electron transfer facilitated? A highly conserved flavinbinding sequence is present in FAD domain. This region contains the residues Arg63,
Tyr65 and Thr66 in porcine liver. The amino acid residue Thr66 is thought to be
responsible for electron transfer from FAD ring and destabilizes the FAD molecule. The
NAD+ molecule is confined in the cavity between NADH- and FAD-domains and
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interacts with the surrounding atoms in the enzyme. The NAD+ is distorted and acquires
an "L-shaped" conformation [46]. The adenine ring stacks itself parallel to the aromatic
ring of Phe223 in the groove. This groove is created by Phe223, Pro247, Pro249 and
Met250. To superimpose the NADH binding domain over FAD domain, almost a 30-40°
twist is required for proper orientation of two binding domains. This orientation is usually
acquired by the water-mediated lateral movement of FAD binding domain.
One of the most important functions of CB5R in plasma membrane is to reduce
the CoQ. This reduced pool of CoQ prevents lipid peroxidation and protects the cell from
oxidative stress [51, 52]. CB5R is also involves in fatty acid chain elongation and
desaturation. Cholesterol synthesis is another well described function of CB5R [53].
CB5R can regenerate some antioxidant molecules such as ascorbate (Asc) and αtocopherol [54]. The major function of the soluble form of enzyme in erythrocytes is to
reduce methemoglobin back to hemoglobin as shown in the Fig 3.3 [55].

Met-Hb

Met-Hb. Reductase

Hemoglobin
(Fe++)

(Fe+++)

NAD +

NADH+H+

Fig 3.3: Reduction of hemoglobin by non-myristolated CB5R form. Methemoglobin is
reduced to hemoglobin by soluble form of CB5R while the NADH is utilized as an electron donor
source. CB5R is also known as methemoglobin reductase.

The metabolic disease associated with the deficiency of CB5R is called
methemoglobinemia. There are two types of this deficiency. Type I involves the
deficiency of soluble form of CB5R in red blood cells. In this type of disease, a well34

tolerated cyanosis with mild symptoms of headache, fatigue and shortness of breath is
observed [56]. Type II is even more severe than type I, and in type II, deficiency of both
forms is observed in red blood cells as well as in leukocytes. The patients with type II
deficiency have severe neurological disorders due to inefficient desaturation of fatty acids
[56].

3.2 Materials and Methods
The methods and materials used for the experimentation with their manufacturer
are listed below:
Myelin

(see

section

2.5.1),

cytochrome

c

(Sigma

7752),

para-

hydroxymercuribenzoic acid (pHMB) (Sigma 55540), TX-100 (Sigma t-9284), Tris (Biobasic 77-86-1), β-NADH (Sigma N6005), KCN (Sigma 60178), CHAPS (Sigma C5070), SDS (Sigma

L-4390), ethanol (BDH B10324-78), ether (EMD Ex-194-6),

potassium chloride (KCl; Sigma 4504), sodium chloride (NaCl; Sigma C-3014), Tween20 (Bio-Rad 161-0781), Dual Colour Precision Plus protein standards (Bio-Rad 1610374), goat anti-CB5R antibody (Pierce PA5-19196), rabbit anti-goat IgG-HRP
secondary antibody (Sigma A-5420), Super Signal West Femto reagents (Thermo
scientific

34094),

ammonium

persulphate

(MP

biomedicals

802829),

tetramethylethylenediamine (TEMED) (Bio-Rad 161-0800).

3.2.1 Western Blot Analysis and Immunohistochemistry
For the SDS-PAGE separation, a 14% resolving gel with 4% stacking gel was
prepared for the investigation of CB5R in brain homogenate, S1 fraction and delipidated
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myelin sample. Myelin fractionation and delipidation was achieved by following the
protocol described in section 2.5.1(A & B) in detail. Gels were loaded with final volume
of 16µl of delipidated myelin, 20µl of S1 detergent fraction, along with the 5X sample
loading buffer and 10µl of 1:10 dilution brain homogenate, 20µl of 1:50 dilution brain
homogenate. Gel was loaded with 5µl of 1:10 dilution of Dual Colour Precision Plus
protein standard. The complete conditions of SDS-PAGE and Western blotting are
outlined in section 2.5.1 (B). For Western blots, membranes were blocked with 5% (w/v)
milk solution for 3 hrs. Subsequently, the membrane was incubated with 3mL of primary
antibody (goat anti-CB5R at a 1:500 dilution) in 1XTTBS solution for 5hrs. After
washing, membrane was incubated with secondary antibody (anti-goat IgG-HRP) for 30
minutes at a 1:80,000 dilution.
Immunofluorescence was done according to the procedure described in section
2.5.1(D). Myelin was diluted in a 1:1000 applied to the slide. The 10µl of diluted myelin
sample was incubated with primary (goat-anti-CB5R) antibody for 1 hrs at room
temperature. The primary antibody was prepared in the dilution of 1:200. After washing
3 times with PBS solution membrane was incubated with secondary fluorescent antibody
Dylight 549 in 1:500 dilution for 30 minutes at room temperature. After washing, images
were taken from Nikon epifluorescence microscope.

3.2.2 NADH Dependent Cytochrome c Reductase Assay
The rate of change of cytochrome c reduction by CB5R was monitored
spectrophotometrically by using 96-well microplate format [57]. A total volume of 200µl
was used for each well and reaction is initiated by the addition of electron donor NADH.
Sample blanks, containing no enzyme, were run in the same manner.
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The activity was determined essentially as described by Navas and co-workers
[57]. The reaction mixture contained 50mM Tris/HCl buffer pH 7.6 with 0.5% (w/v) TX100, 10-30µg protein (myelin), substrate cytochrome c from 50-600µM and 250µM
NADH. Enzyme activity was determined by monitoring the enzyme-dependent increase
in absorbance at 550nm for 5 minutes at the intervals of 20-40 seconds at 37°C. For
inhibition studies, different concentrations up to 10µM of pHMB were used. The 20mM
stock solution of pHMB was prepared by dissolving 0.036g pHMB into 5mL milliQ. The
activity was expressed as ∆Abs/min or micromoles of cytochrome c reduced per minute
using an extinction coefficient of 29.5mM-1 cm-1.

3.2.3 Methodology of Detergent Fraction Assay
For detergent fractionation, the myelin was treated as the procedure described in
section 2.5(A). The overall procedure of the detergent fraction assay was similar as
described in section 3.2.2 with only exception that 1.5% (w/v) CHAPS supernatant and
pellet (S1, P1) were assayed with supernatant and pellet of 2% (w/v) TX-100 (S2, P2).
The assay mixture contained 50mM Tris/HCl buffer pH 7.6 with 0.5% (w/v) TX-100,
50µl of each detergent fraction, 100µM of cytochrome c and 250µM NADH.

For

controls, 20µg of myelin was used instead of detergent fractions. Total volume in well
was made up to 200µl by addition of water. The activity was measured as described
above. The enzyme activity in myelin was compared with the activities in different
detergent fractions (S1, S2, P1 and P2).
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3.2.4 Kinetic and Statistical Analysis
For kinetic analysis, online curve and surface fitting resources from zunzun.com
(least square fit model) were used to estimate the Vmax and KM parameters of CB5R with
cytochrome c substrate. Statistical analysis was performed using Microsoft Excel 2010.
T-tests were used for all analysis including the myelin dose response, substrate dose
response and on inhibition test. Statistical significance was established at p≤0.05 at 95%
confidence level.

3.3 Results and Discussion
Borgese et al. determined the sub-cellular localization of CB5R using
radioimmunoblotting analysis in rat liver, and found that CB5R is present in smooth
microsomes, Golgi bodies, lysosomes, the plasma membrane and the outer membrane of
mitochondria

[58].

In

this

current

study,

Western

blot

analysis

and

immunohistochemistry identified the CB5R in the myelin membrane (see Fig 3.4). In Fig
3.4A, immunohistology of CB5R confirmed the enzyme localization in myelin
membrane. To further investigate the distribution within the membrane, Western blot
analysis was performed on the detergent fractions (Fig 3.4B). CB5R was present in the
S1 fraction, whole myelin, and in brain homogenates (see Fig 3.4B). The blot also
showed that CB5R is expressed in two isoforms; one with a molecular weight of ~35kDa
which may represent the form bound to membrane while the other isoform with
molecular weight of ~33kDa which may represent the form lacking myristoylated region.
The myristoylation confers hydrophobicity to the protein and facilitates the
insertion of the protein into the membrane. The form lacking the myristoylated moiety
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still may be associated with the myelin membrane, and thus be a tightly bound peripheral
membrane protein either through various protein-protein or lipid-protein interactions.
Another possibility is that the non-myristoylated form was produced as a degraded
product of CB5R membrane bound form. The non-myristoylated form as a peripheral
membrane protein might be an additional system for reduction of CoQ pool to avoid lipid
peroxidation and ascorbate regeneration. Previous studies demonstrated that both the
non-myristolyated (soluble) and myristolyated form (membrane-bound), were detected in
cultured neurons, whereas the membrane-bound form was only detected in synaptic
plasma membrane vesicles [59].
The detection of CB5R in the S1 fraction indicates that the enzyme may be
localized in the lipid raft microdomain. Further separation of this fraction on a sucrose
buoyant density gradient would confirm this [41]. Samhan et al. found evidence that
CB5R is present in lipid rafts and is associated with caveolin-rich regions of plasma
membrane of neuronal cells [60]. Caveolin is the most abundant protein in the caveolae
microdomain and controls the cholesterol trafficking.
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A

B

Fig 3.4: Immunodetection of CB5R in the myelin membrane. Panel (A):
Immunofluorescent image of CB5R in myelin membrane. Diluted myelin (1:1000) was
incubated with cytochrome b5 primary antibody in 1:200 dilution for one hour and after washing
subsequently incubated with secondary antibody anti-goat DyLight 549 in a 1:500 dilution for
30 minutes. Image was taken with 100X oil immersion lens and with Nikon 300 epifluorescent
microscope. Panel (B): Western blot for cytochrome b5 reductase. A 14% resolving gel with
4% stacking gel was prepared for the examination of CB5R in brain homogenate (BH), S1
fraction and delipidated myelin sample (DP). Proteins were transferred to nitrocellulose
membrane at 200mA for 2 hrs. Membrane was blocked with milk solution and then subsequently
incubated with primary and secondary antibodies. For enhanced chemiluminescence, ECL
substrate was used and immediately after that image was taken with the 4000 VersaDoc imaging
system.
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3.2 Measurement of Cytochrome b5 Reductase Activity in Myelin
Membrane
The endogenous substrates of CB5R enzyme are cytochrome b5 (Cb5) and CoQ.
Recombinant Cb5 is available commercially but it is cost prohibited. High levels of Cb5
are found in liver cells but its extraction from liver is difficult [57]. In cells, the reduction
of Cb5 is essential, as it is a key player in cholesterol synthesis [61]. For experimental
purposes, an analog of Cb5, cytochrome c, is extensively used. The CB5R activity is
determined spectrophotometrically as the NADH-dependent reduction of cytochrome c
and also quantified with the inhibitor pHMB [62]. The measurement of cytochrome c
reduction was taken at 550nm as it is the wavelength at which cytochrome c (reduced
form) shows maximum absorption. The enzyme activity was determined by following the
reduction of cytochrome c with the electron donor, NADH. Hence, by measuring the rate
of reduction of cytochrome c, the CB5R activity can be estimated. Following reaction is
catalyzed by CB5R. Moreover, the standard electrode potential E´° (235mV) of
cytochrome c (Fe3+/ Fe2+) oxidized form is fairly large (positive value) and thus the
ferrous form readily to accepts an electron [63].

NADH + H+ + 2 cyto c (Fe3+)

Reductase

NAD+ + 2 cyto c (Fe2+)

(3.1)

The enzymatic activity of CB5R in myelin membrane was measured by the
associated activity of cytochrome c reductase. A typical rate of reaction of cytochrome c
reduction with the myelin membrane is illustrated in Fig 3.5. The slope (change in
absorbance/min) and enzyme activity were calculated as described in section 2.4.1. All
slopes were corrected for the background (negative control without enzyme).
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Fig 3.5: A typical graph depicting cytochrome c reductase activity. Rate of change of
cytochrome c reduction was determined by plotting the absorbance versus time. Same
procedure was used for blanks as well. Sample contains myelin, water, buffer, cytochrome c
and NADH. The blank (negative control) contains no myelin.

3.5.1 Enzyme Assay with Myelin Detergent Fractions

Fig 3.6: Comparison of myelin detergent fractions for NADH:cytochrome c reductase
activity. The activity of enzyme in non-treated myelin is taken as the control. The rate of
each fraction (50µl) and myelin (20µg) was assayed in the presence of 100µM of cyto c
and 250µM NADH at 37°C over 5 minutes (see methods for complete details). All error
bars are ±SE.
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The enzyme activity in whole myelin sample was compared to the different
myelin detergent fractions (see Fig 3.6). On an equi-volume basis, the highest activity
was observed in the S1 fraction (2.44 x 10-4 µM/min) and the lowest activity was in the
P2 fraction (1.37 x 10-7 µM/min) and thus, most of the CB5R associated activity is
distributed into the CHAPS supernatant fraction. This also supports the findings of
Western blot. The enzyme activities in detergent fractions, other than S1, can be seen.
These activities might be due to the presence of other reductases, oxidases or
dehydrogenases.

Activity (µM/min)

3.00E-05
2.50E-05
2.00E-05
1.50E-05
1.00E-05
5.00E-06
0.00E+00

0

5

10

15

20

Myelin (µg)

Fig 3.7: NADH: cytochrome c reductase activity as a function of amount of myelin. 50mM
Tris-HCl buffer pH 7.6 with 0.5% (w/v) TX-100, was assayed with 5, 10, 20µg myelin, 100µM
cytochrome c and 250µM NADH. Measurement was taken spectrophotometrically at 550nm at
37°C. Results are produced in duplicate and corrected for background. The error bars are ± SE
(standard error).

Further characterization of NADH: cytochrome c reductase activity was
completed with whole myelin. Fig 3.7 illustrates that the enzyme activity is directly
proportional to the amount of protein added. Thus the NADH: cytochrome c reductase
activity is a function of myelin concentration. Dose response of myelin also shows that
enzyme(s) is in active form.
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Enzyme activity at various substrate concentrations is very important in
determining enzyme steady-state kinetics model. An evaluation of the dose response of
the substrate, cytochrome c, was done to generate the kinetic curve (see Fig 3.8).

*

A

B

3.8: NADH: cytochrome c reductase activity as a function of amount of substrate. Panel (A)
Enzyme activity in myelin. 50mM Tris/HCl buffer pH 7.6 with 0.5% (w/v) TX-100, was
assayed with 20µg myelin, 50, 100, 250, 500 and 600µM cytochrome c and 250µM NADH.
Measurements were taken spectrophotometrically at 550nm at 37°C. Results are produced in
duplicate and corrected for background. The error bars are ± SE (standard error). The t-test
results indicate no statistical significance (*p=0.35) of more than 95% confidence interval in
increase in enzyme activity between 500 and 600µM of cytochrome c concentration. Panel (B)
Data fitted with kinetic software (zunzun.com) to determine apparent KM and Vmax.. The solid line
shows the data, whereas dashed line depicts the 95% CI.
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Substrate dose response curve showed that enzyme follows a hyperbolic curve
representing the typical Michaelis Menten model. At 600µM, the enzyme is saturated
with substrate and reaches at its maximum rate Vmax and reaction follows the zero order
kinetics and becomes independent of amount of substrate added. The kinetic parameters,
Vmax and KM were estimated as 6.59 x 10-5 µM/min and 151 µM, respectively.
Enzyme inhibitors are important in studying metabolic reactions and
pharmacological modeling. Some physiological inhibitors as well as artificial inhibitors
are well known and are used in drugs. Typically in kinetic studies of an enzyme, the
assays are validated when a potent inhibitor reduces the specific enzymatic activity. The
myelin samples were exposed to progressive increasing concentration of pHMB (see Fig
3.9), which is a well-known competitive reversible inhibitor of CB5R enzyme [57].

Fig 3. 9: Structure of pHMB. Para-(hydroxymercuribenzoate (pHMB) also known as 4(hydroxymercurio)benzoate forms mercury-sulfur covalent bond with thiol group of cysteine
residues.

Organic mercurial compounds such as pHMB and para-chloromercuribenzene
sulfonate (pCMBS) reacts with cysteine sulfhydryl groups. The pHMB is relatively
hydrophobic in nature and can partition into the membrane, reacting with more "buried"
sulfhydryl groups. In contrast, pCMBS can react only with "exposed" sulfhydryl groups.
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A myelin sample without inhibitor was used as the control and considered as
having 100% oxidoreductase activity (see Fig 3.10). The cytochrome c reductase activity
was significantly decreased by increasing concentration of the inhibitor, pHMB. At
10µM of pHMB the enzyme activity was over 90% inhibited. In addition, 50% inhibition
(IC50) of enzyme activity was achieved by 1µM pHMB. Enzyme activity assay of
cytochrome c reductase and pHMB-mediated inhibition is another confirmation of
presence of CB5R enzyme in myelin membrane. In human CB5R, four cysteine residues
(Cys203, Cys273, Cys283 and Cys297) are present. Among four residues, two residues,
Cys273 and Cys283 are located near the NADH binding domain. The Cys273 plays a
vital role in the electron transfer and also aids in maintaining the native conformation of
the protein [64].

Fig 3.10: Inhibition of cytochrome c reductase activity by pHMB.
Measurements were taken at 550nm at 37°C. Results are produced in triplicates
and corrected for background. The 20µg myelin was assayed with 100µM
cytochrome c and 250µM NADH. The error bars are ± SE. The t-test results
indicate a statistical significance of more than 95% between 0 and 0.1µM
(*p=0.01) and between 5 and 10µM pHMB (**p= 0.04).
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Since it was established that CB5R is present in myelin membrane, it is now
necessary to differentiate the detected activity from mitochondria to ensure that activity is
at the level of plasma membrane. To achieve this purpose, potassium cyanide (KCN) was
used.

Cyanide is

a

potent

inhibitor

of cellular

respiration,

acting

on

mitochondrial cytochrome c oxidase (complex IV), by blocking the electron transfer,
inhibits the oxidative phosphorylation. A previous study showed that 1.0mM of KCN
inhibits 70% activity of cytochrome c oxidase in mitochondria [65]. Effect of KCN
inhibition on CB5R is depicted in Fig 3.11. The cytochrome c reductase activity in the
myelin membrane is insensitive to the inhibitor KCN. In addition, the insensitivity to
KCN shows that cytochrome c reductase activity is at the level of plasma membrane and
there is no mitochondrial contribution or contamination.

Fig 3.11: Attempted inhibition of cytochrome c reductase activity by KCN. The activity
of 10µg myelin was assayed with 50mM Tris buffer, 100µM cytochrome c and various
concentrations (0, 0.1, 0.5, 2.0 mM) of KCN. Reduction of activity is monitored for 5
minutes at the interval of 20 second at 550nm. Reactants were allowed to react at 37 °C.
Results were produced in triplicate and corrected for non-enzymatic activity. The error bars
are ± SE. The t-test results indicate a statistical significance of more than 95% confidence.
The value of t-test is *p = 0.438.
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3.6 Conclusions
In this study, for the first time, the presence of t-PMET enzyme, CB5R, was
detected in myelin membrane. CB5R is present in functional enzymatic form and may be
localized to the lipid raft domain. The CB5R activity was measured with an assay
utilizing the NADH-dependent cytochrome c reduction. The substrate dose-response
curve revealed that enzyme follows the Michaelis Menten model and their kinetic
parameters Vmax and KM were estimated as 6.59 x 10-5 µM/min and 151µM, respectively.
The enzyme activity was 90% inhibited with 10µM pHMB. Furthermore, both the
myristoylated and non-myristoylated enzyme are associated with the myelin membrane.
The function(s) of the isoforms of CB5R in myelin remains to be elucidated. The
confirmed presence of CB5R in myelin membrane supports the hypothesis that t-PMET
is assisting myelin membrane.
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CHAPTER 4
Investigation of NAD(P)H: Quinone
Oxidoreductase 1 (NQO1) in the
Myelin Membrane
In the following chapter, a study was conducted to investigate the presence of
NQO1 enzyme and its associated activities in the myelin membrane using various
substrates such as menadione, dichlorophenol indophenol (DCPIP) and phenazinium
methyl sulfate (PMS). To examine enzyme specificity, various inhibitors such as DPI,
pHMB and the potent inhibitor of NQO1, dicoumarol, were used. The NQO1 presence
was also verified with immunohistochemistry and Western blotting.

4.1 Introduction
NAD(P)H: quinone oxidoreductase 1 or NQO1, previously known as DTdiaphorase and quinone reductase, is a flavo-homodimeric protein and it catalyzes the
two electron reduction of various quinones and quinone imines. Each subunit has a
predicted molecular weight of 30kDa. In humans, the NQO1 gene is located on the 16th
chromosome and is ~20 kb in length [66, 67]. NQO1 can utilize, NADH or NADPH,
both as an electron donor. In erythrocytes, NQO1 has electron donor preference for
NADPH [68, 69]. The localization of NQO1 within the cell is dependent on the cell type
and the function of this enzyme in this particular cell [70]. Ross et al. described the
enzyme’s presence in the nucleus; however, under oxidative stress, through an unknown
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mechanism, the enzyme can be translocated to the plasma membrane [70]. Other
researchers described the NQO1 as a cytosolic protein but the presence in the nucleus,
mitochondria and plasma membrane has been confirmed [17].

Fig 4.1: Structure of the human NQO1 enzyme. The two different lobes are represented by the
two different colours. The FAD binding domain is at the interface of the dimers. Figure taken
from reference [71].

This homo-dimeric flavoprotein has its catalytic site at the dimer interface. Each
monomer subunit consists of 273 amino acid residues and its own prosthetic group, FAD
[72]. Each monomer contains two domains; a catalytic N-terminus domain which is
larger and comprised of 1-220 amino acid residues, and the small C-terminus domain
from residues 221-273 (Fig 4.1) [72]. The one side of the catalytic pocket is formed by
FAD-binding domain while other side of the wall is formed by the residues of the larger
domain [68, 73]. The amino acid residues Tyr155 and His161, (in the human sequence)
are present in the active site (Fig 4.2). The NQO1 enzyme is capable of metabolizing a
wide range of substrates. Due to this ability of the enzyme, the binding site of substrate
can accommodate a large variety of ring containing compounds and the enzyme shows an
induced-fit model [72].
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NQO1 catalyzes the two-electron transfer from NAD(P)H to FAD and then from
FADH2 to a quinone (for example, CoQ) by a ping-pong mechanism [72]. The
nicotinamide ring of NAD(P)H stacks parallel to the FAD isoalloxazine ring and
facilitates the efficient transfer of electrons. The donor, NADH, in the form of NAD+ is
released after transferring electrons. Then the quinone binds to the enzyme, and it
becomes reduced and released. Dicoumarol is a potent competitive inhibitor of NQO1
enzyme. Dicoumarol interacts with FAD, and prevents NAD(P)H binding [71]. The
schematic of the catalytic mechanism is shown in Fig 4.2. In the enzyme, the NADPH
binding site and quinone binding site are overlapping.

Fig 4.2: A proposed catalytic mechanism of human NQO1. NADH donates its electron
to the FAD prosthetic group. The electrons from FADH2 are transferred to the substrate CoQ. In
the active site, Tyr and His acts as a proton/acceptor. Figure from reference [17].
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One of the major functions of NQO1 in the plasma membrane is cellular defence,
by reducing the pool of CoQ. CoQ is also an endogenous physiological substrate of
NQO1 and the other endogenous substrates are unknown [74]. NQO1 reduces the CoQ
by a two electron reduction, thus avoiding the formation of the semiquinone and
subsequently, O2-and H2O2 formation [75]. In addition, NQO1 also demonstrates
superoxide scavenging activity [76]. Another important function of the enzyme in the
plasma membrane as well as in other localizations is the detoxification of xenobiotics
[68, 77]. Moreover, enzyme is involved in stabilizing the p53 gene product [78]. The
functions of NQO1 are summarized in Fig 4.3.

Reduction
of CoQ
Chemo
Protection

Regulation of
Sirtuins

Superoxide
Scavenger

NQO1
Functions

Stabalization
of p53 Gene

NAD+/NADH
Ratio Modulator

Lipid
Metabolism
20S Proteosomal
Protection

Fig 4.3: Schematic of functions of NQO 1 enzyme. Important functions of
NQO1 enzymes are modulation of electron donor ratios, protection from proteaosomal
attack and reduction of CoQ. Some functions are tissue specific.
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4.2 Materials and Methods
The reagents and materials used for the experimentation with their supplier and
product number are listed below:
Myelin from mouse brains (see section 2.5.1), Tris (Bio-Basic 77-86-1),
menadione (2- methyl-1, 4-naphthoquinone; Sigma M5625), DCPIP (2, 4-dichlorophenol
indophenol; Sigma 33125), dicoumarol (3, 3’-methylene-bis (4-hydroxycoumarin);
Sigma M-1390), DPI (diphenyleneiodonium chloride; Santa Cruz sc-202584), pHMB
(Sigma 55540), dimethyl sulphoxide (DMSO) (Fisher Scientific Co. BPB231),
cytochrome c (Sigma 7752), rotenone (Sigma R8875), KCN (Sigma 60178),
chloramphenicol (Sigma C0378), rabbit anti-NQO1 antibody; Pierce), mouse anti-rabbit
IgG-HRP secondary antibody (Sigma A0545), super-signal West Femto reagent (Thermo
Scientific).

4.2.1 Enzyme Activity Assays
The NQO1 activity was measured by three related activities; menadione-mediated
cytochrome c reductase activity, PMS-mediated WST-1 reductase and DCPIP reductase
activity. In all of these activities, NADH or NADPH is utilized as an electron donor. The
general procedure of enzyme assay was the same as described in section 2.3. All three
procedures for measuring enzyme activities are described below:

(A)

Menadione-Mediated Cytochrome c Reductase Activity
Myelin protein (20-40µg) was assayed with 10µM menadione, 70µM cytochrome

c and 250µM NADH, in final concentration. The buffer was 50mM Tris/HCl, pH 7.6
with 0.1% TX-100. Total volume in the well was 200µl and adjusted with the milli Q
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water. The various concentrations of inhibitors dicoumarol (0, 50, 100, 500µM) and DPI
(0, 10, 50, 100µM) were used. Measurements were taken at 550nm, at 37°C and
monitored for 5 minutes at the kinetic interval of 20 seconds. The extinction coefficient
of reduced cytochrome c at 550nm was taken as 29.5mM-1cm-1 [79].

(B) PMS-Mediated WST-1 Reductase Activity
Water soluble tetrazolium generation 1 (WST-1) is another diagnostic tool used to
measure the NQO1 activity [80]. An intermediate electron carrier, PMS, is also used in
conjunction with WST-1. The activity was measured as reduction of WST-1 increase in
absorbance at 37°C for 15 minutes at an interval of 30 seconds. The extinction coefficient
of the reduced formazan at 438nm was taken as 37 mM-1cm-1 [80].
The assay mixture consists of 100mM potassium phosphate, 2mM EGTA buffer
(pH 7.0), 200µM of NADH, 20µM PMS and 10µg myelin. To initiate the reaction
300µM of WST-1 was added to the mixture. To determine the specificity of the activity,
various concentrations of dicoumarol (0, 10, 20, 50 and 100µM) were used.

(C) DCPIP Reductase Activity
The same method as described previously was used to measure the DCPIP
reductase activity [81]. The myelin (20-40µg) was assayed with increasing concentrations
(0-600µM) of DCPIP. NQO1 activity was measured with or without the addition of FAD.
To measure the activity with FAD, 5µM of FAD was used. The following inhibitors were
tested: dicoumarol (0, 10, 25, 50, 75, 100, 250, 500µM) prepared in DMSO or in 0.1N
NaOH, DPI (0, 10, 100, 500µM) 30mM stock solution in DMSO, pHMB (0, 1, 5, 10, 50,
100µM) 20mM stock solution in water, KCN (0, 3, 5, 10, 50µM) 10mM solution in
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water, chloramphenicol (0, 50, 100, 200, 400, 500µM) 10mM in DMSO, rotenone (0, 20,
50, 100, 500µM) 10mM solution in DMSO and DMSO (w/v) (0, 2.5, 5, 7.5, 10, 17.5%)
were used. The structures of these inhibitors are drawn in Table 4.1. The buffer contained
25mM Tris/HCl, pH 7.4, 0.01% (w/v) Tween-20 and 0.07% (w/v) BSA in final
concentration. To initiate the reaction, 200µM of NADH was added. Activity was
measured as a decrease in absorbance at 600nm, at 37°C and monitored for 5 minutes at
20-40 seconds interval. The extinction coefficient of oxidized form of DCPIP at 600nm
was taken as 21.0 mM-1 cm-1 [81].

4.2.2 Measurement of Reductase Activity in Detergent Fractions
For detergent fractionation, myelin was treated as the procedure described in
section 2.5.1(A). The menadione-mediated cytochrome c reductase assay was conducted
with the 1.5% (w/v) CHAPS supernatant (S1) and pellet (P1) and the 2% (w/v) TX-100
supernatant (S2) and pellet (P2). The assay mixture contained 50mM Tris/HCl buffer (pH
7.6 with 0.5% TX-100), 50µl of each detergent fraction, 100µM of cytochrome c and
250µM of NADH.

For the positive control, 20µg of myelin was used instead of

detergent fractions. The total volume in the well was made up to 200µl by addition of
water. The enzyme activity in myelin was compared with the activities in different
detergent fractions (S1, S2, P1 and P2).

4.2.3 Western Blot Analysis and Immunohistology
For the SDS-PAGE separation, a 14% resolving gel with 4% stacking gel was
prepared for the investigation of NQO1 in the brain homogenate and detergent fraction
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samples (S1, S2, P1 and P2). The procedure of SDS-PAGE and Western blotting was
followed as outlined in section 2.5.1(C). Gels were loaded with final volume of 20 µl of
TABLE 4.1: Chemical structures of used inhibitors. Inhibitors analogue to NAD(P)H
are shown with their chemical structure.

INHIBITOR

CHEMICAL STRUCTURE

Dicoumarol

Diphenyleneiodonium

Chloramphenicol

Rotenone

Dimethyl sulphoxide

each detergent fraction, along with the 5X sample loading buffer and 10µl of 1:10
dilution brain homogenate, 20µl of 1:50 dilution brain homogenate. Gels were loaded
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with 5µl of 1:10 dilution of Dual Colour Precision Plus protein standard (Bio-Rad). For
the Western blot, the membrane was incubated with 3mL of primary rabbit anti-NQO1
antibody for 5hrs. The dilution of antibody was 1:1000. After washing, the membrane
was incubated with a secondary antibody, anti-rabbit IgG-HRP, for 30 minutes at a
1:80,000 dilution. After washing three times with 1XTTBS, the membrane was incubated
with 3mL of super signal west femto solution for 5 minutes and image was taken
immediately.
To confirm the NQO1 presence in the myelin membrane, immunohistochemistry
was also performed. To achieve this, myelin was diluted to a 1:1000 ratio. The diluted of
myelin (10µl) is incubated with 40µl of NQO1 primary antibody (Pierce PA5-19624) in
a 1:200 dilution and 40µl of primary antibody of myelin basic protein (MBP) (Millipore
LV 1583525) in a 1:200 dilution for 1 hour at room temperature [19]. Subsequently,
myelin is incubated with secondary anti-rabbit IgG antibody Dylight 549 (Thermo
Scientific 35557) and anti-rat IgG Dylight 488 (Millipore MAB386). The dilution of each
secondary antibody was 1:500. The image was taken with the Nikon fluorescent
microscope with 100x oil immersion lens.

4.2.4 Kinetic and Statistical Analysis
For kinetic analysis, online curve and surface fitting resources from zunzun.com
(least-square model) were used to estimate the Vmax and KM parameters of NQO1.
Statistical analysis was performed using Microsoft Excel 2010. The t-test was used for
all analysis including myelin dose response, substrate dose response and on inhibition
test. Statistical significance was established at p≤0.05 for a 95% confidence level.
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4.3 Results and Discussion
NQO1 is present in a variety of cells and tissues and its localization in the cell
depends on the cell's function. Jaiswal et al. described the NQO1 activity in almost all
cell types [82]. Although NQO1 is mainly a cytosolic protein, but it is also present in
other cell fractions. In humans, NQO1 is present abundantly in epithelial and endothelial
cells but overexpressed in lung, colon and breast cancer [83]. Hyun et al. found the
NQO1 in plasma membrane of neuroblastoma cells [84]. NQO1 has been detected in
astrocytes and myelin-laden macrophages within MS lesions. In addition, NQO1 was
found in a subset of OLs at the borders of active plaques [85]. The NQO2 and mNQO are
the two major isoforms of NQO. NQO2 is 43 amino acids shorter than NQO1. The
nucleotide sequence from exon 3-6 is highly conserved between NQO1 and NQO2 [87].
Contrary to NQO1, which is expressed in almost all cell types, NQO2 is expressed in
heart, lungs, brain, liver and skeletal muscles. NQO2 can use DCPIP as a substrate but
uses NADH as an electron donor poorly [87]. The preferential electron donor of NQO2 is
dihydronicotinamide riboside (NRH) and the enzyme functions mainly as a
nitroreductase [87]. Microsomal NQO (mNQO), another isoform of NQO, which is
highly insensitive to dicoumarol is identified in liver microsomes and its molecular
weight found to be ~18kDa [88].

4.3.1 Immuno Detection of NQO1 in the Myelin Membrane
To confirm the presence of NQO1 in the myelin membrane Western blot and
immunohistochemistry were performed. Fig 4.4 A & B represents the results of Western
blot

and

immunoflourescent

image,

respectively.
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The

Western

blot

and

immunohistochemistry confirmed that the enzyme is present in the myelin membrane.
Furthermore, Western blot revealed the truncated form of the NQO1 in the myelin
membrane as demonstrated by the band at ~13kDa (see Fig 4.4A).
A

B

Fig 4.4: Immuno detection of NQO1. Panel (A): NQO 1 Western blot: Blot was made with 14
% resolving and 4 % stacking gel. Blot shows brain homogenate and detergent fractions (S1, S2,
P1, P2) samples. Image was taken with 4000 VersaDoc. Panel (B): Immunoflourescent image
of NQO1: Nikon Fluorescent microscope (100X oil immersion lens) is used to detect NQO1.
Green colour shows the NQO1 while the blue colour shows the myelin basic protein (MBP).
59

In addition, the Western blot confirmed that the enzyme is present in the S1
detergent fraction at ~13kDa as well as at ~27kDa (a vary faint band can be seen). In the
brain homogenate, a very prominent band at ~13kDa can be seen along with two other,
relatively light, bands at 27 and 30kDa, respectively. The NQO1 full length is represented
by the band at 30kDa. Immunofluorescent image also confirmed the presence of NQO1
in the myelin membrane. Moreover, the image reveals that NQO1 and MBP are not colocalized (Fig 4.4 B).
Gasdaska et al. discovered a novel alternatively splice form of NQO1 mRNA (Fig
4.5) in normal and tumour colon cells [89]. The new isoform lacks the exon 4
(corresponding to mRNA residues 102-139), which corresponds to the quinone binding
domain. This non-functional form is 114 base pairs smaller than NQO1 full length (20
kb) form, and is subjected to the further degradation. In rat NQO1, different residues
regulate different functions. Likewise, Tyr128 is significant for dicoumarol binding and
Lys76, Phe116, Glu117 and Asp163 for NADPH binding [89]. The reason for the nonfunctional form could be the absence of these above mentioned amino acid residues.

Fig 4.5: Structure of NQO1 mRNA and position of spliced exon 4. Fig taken from
reference [89].
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Jaiswal et al. discovered the two isoforms of NQO, NQO1 and NQO2, in rat liver
cells in addition to microsomal NQO (mNQO). Moreover, they found that rat mNQO has
a molecular weight of ~18kDa. In addition, mNQO was found along with the full length,
~29kDa, cytosolic rat NQO1. Interestingly, mNQO showed the approximately three to
four times more affinity for electron donor NADH over NADPH. The estimated
molecular weight of the truncated form that we found in mouse myelin membranes was
~13kDa, whereas the molecular weight of rat mNQO is ~18kDa.
In Fig 4.4A, the brain homogenate (1:10 dilution) and S1 fraction have a band at
~27-28kDa which may represents NQO1, or NQO2. Mouse NQO1 and NQO2 have a
49% sequence homology and the antibody used in the experiment was polyclonal [90].
Thus, there is a possibility that NQO1 antibody binds to the NQO2 which has a molecular
weight of ~26kDa. As mentioned earlier, NQO1 has two domains, one is the compact Nterminus (1-220 amino acid residues), and the other C-terminus (221-273) is less
compact. Previous studies showed that the NQO1 carboxy-terminus is cleaved off due to
the proteolytic attack in the absence of NAD(P)H or FAD [90]. Another possibility is that
~ 27kDa band is generated due to the degradation of NQO1 in absence of electron donor
or prosthetic group.
4.3.2 NQO1 Associated Activities in the Myelin Membrane
In this research study, NQO1 activity was measured through three associated
activities; menadione-mediated cytochrome c reductase activity, PMS-mediated WST-1
reductase activity and lastly, DCPIP reductase activity. The potent inhibitor, dicoumarol,
should affect all three activities.
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4.3.2 (A): Menadione -Mediated Cytochrome c Reductase Activity
Quinones belong to the Vitamin k3 class, and are used as intermediate electron
carriers for various reactions. Menadione-mediated cytochrome c reduction by NQO1 is
monitored as increase in absorbance at 550nm [79].
The NQO1 cannot reduce the cytochrome c directly, thus a mediator, menadione,
is required. The electron flow from NADH via menadione will reduce the cytochrome c
(oxidized form). As a consequence, the concentration of cytochrome c (reduced form)
will gradually increase with correspondence to its absorbance. Thus, NQO1 will catalyze
the two electron reduction of menadione to menadiol with NADH as the electron donor
(expression 4.1). Then non-enzymatically, menadiol will reduce cytochrome c
(expression 4.2).

NADH + MD (menadione)
MDH2 + 2cyt c (Fe3+)

NQO1

NAD++MDH2

MD + 2cyto c (Fe2+)

(Menadiol) (4.1)
(4.2)

A typical rate of menadione-mediated cytochrome c reduction with myelin is
illustrated in Fig 4.6. The initial reaction rate was determined by plotting the absorbance
against time for sample and negative control(blanks). All reaction rates were corrected
for the non-enzymatic reduction of cytochrome c and menadione.
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Fig 4.6: Typical reaction rate of menadione-mediated cytochrome c
reduction by myelin. The sample contains myelin whereas, the negative
control contains no myelin and represents the non-enzymatic reduction.

Enzyme Assay with Myelin Detergent Fractions
To determine the enzyme localization in the myelin membrane and its
microdomain, a strategy was developed to compare the menadione-mediated cytochrome
c reductase activity of enzyme in different myelin detergent fractions. To obtain myelin
fractions, 500µg of myelin was treated as described in section 2.5.1(A). An enzyme
activity assay as described above was performed with detergent fractions of CHAPS
extract S1 and P1 (the supernatant and pellet, respectively) and TX-100 extract S2 and
P2, (supernatant and pellet).
By comparing the activities of myelin detergent fractions (S1, S2, P1 and P2) on
equi-volume basis with the activity of whole myelin, it can be concluded that most of the
reductase activity is distributed into the S1 fraction (Fig 4.7). The activity in S1 fraction
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Fig 4.7: Comparison of myelin detergent fractions for menadione-mediated cytochrome c
reductase activity. The reaction rate of each fraction (50µl) and myelin (20µg) was assayed in
the presence of 70µM cytochrome c, 10µM menadione and 250µM of NADH at 37°C over 5
minutes. All results were produced in triplicate and corrected for non-enzymatic activity. The
error bars are ±SE.

is higher than control myelin sample may be due to the enzyme semi-purification.
Furthermore, Western blot analysis result (Fig 4.4A) also confirmed the enzyme presence
in S1 fraction. NQO1 and the reductase activity are either in the membrane region,
completely solubilized by CHAPS, or in detergent resistant membranes representing lipid
rafts. The activities in other fractions (S2, P1, and P2) might be due to the presence of
other oxidoreductases.
Further characterization of the menadione-mediated cytochrome c reductase
activity was completed with whole myelin. Fig 4.8 illustrates the result of enzyme doseresponse analysis. Fig 4.8 depicts that rate of absorbance per unit time is proportional to
the amount of protein added. In short, there is a direct relationship in reduced cyto c
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Fig. 4.8: Cytochrome c reduction via menadione activity as a function of amount of myelin.
Assay contained 50mM buffer with 20, 30, or 40µg of myelin protein and 70µM cyto c, 10µM
menadione and 200µM NADH. Measurement was taken spectrophotometrically at 550nm at
37°C. Results are produced in duplicate and corrected for background. The error bars are ±SE
(standard error).

concentration and enzyme activity. Furthermore, it can be assumed that cytochrome c
reduced form is produced by the activity of menadione-mediated cytochrome c reductase
activity, which may be due NQO1 presence in myelin membrane.
Several inhibitors, such as rotenone, DPI and capasicin, are typically used to
inhibit the activities of oxidoreductases and flavoproteins. Dicoumarol, a competitive
inhibitor, is widely used to inhibit the activity of NQO1 [90]. Dicoumarol inhibits the
activity of Vitamin K dependent reductases and has an anti-coagulant property by
decreasing the prothrombin level in Vitamin-K dependent proteins [91]. NQO1 is very
sensitive to dicoumarol and typically, 10nM to 10µM is required to inhibit the activity in
different species including humans [91].
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A

B

Fig 4.9: Attempted inhibition of menadione-mediated cytochrome c reductase
activity by inhibitors: (A): Dose response of dicoumarol: Asaay mixture consists of 50mM
Tris buffer, 20µg myelin in (1:3) dilution, 10µM menadione, 70µM cytochrome c, 0, 50, 100,
500µM dicoumarol and finally 200µM NADH. Panel (B): Dose response of DPI: 50mM Tris
buffer, 20µg myelin, 10µM menadione and 70µM cytochrome c, 200µM of NADH and 0, 10, 50,
100µM DPI. The statistical analysis showed the p values as *p= 0.028 and **p= 0.051. For both
panels, (A) & (B), Measurement was taken spectrophotometrically at 550nm at 37°C. Electron
transfer was monitored for 5 minutes at the interval of 20 sec. Results were produced in triplicate
and corrected for non- enzymatic activity. The error bars are ± SE (standard error).

Result of dicoumarol-dependent inhibition is shown in the Fig 4. 9 (A). It is
evident from the results that 35% activity of cytochrome c reductase was inhibited with
50µM dicoumarol but the cytochrome c reductase activity was

increased at higher

concentration (500µM) of dicoumarol (Fig 4.9A). The increase in activity might be due to
dicoumarol in the buffer. Only a modest degree of inhibition (35%) was observed at
50µM dicoumarol. Typically, NQO1 is fully inhibited with nanomolar concentrations of
dicoumarol. It may be concluded that oxidoreductase activity is not only due to the NQO1
but other enzymatic activities are also contributing.
DPI is another inhibitor of flavoproteins such as NADPH oxidases. It is also a
potent inhibitor of nitric oxide synthase (NOS) in macrophages and endothelial cells.
Typically, 20-25µM of DPI is required to inhibit 80% of NOS activity in endothelial
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cells. The results of DPI-dependent inhibition of menadione-mediated cytochrome c
reductase in myelin is shown in Fig 4.9(B). The activity is partially inhibited (~20%), by
50µM DPI. Besides NQO1, there are several other flavoproteins that are present in the
myelin membrane such as CB5R. As mentioned earlier, a recent study shows that CB5R
and neuronal NOS (nNOS) are associated with the caveolin protein in microdomains [92,
93]. If various flavoproteins are closely associated the inhibition of one may affect the
activity of another.

4.3.2 (B): PMS-Mediated WST-1 Reductase Activity
As menadione reductase activity is not inhibited by dicoumarol, another substrate,
water soluble tetrazolium generation 1 (WST-1) was used along with the electron carrier
1-methoxy-5-methyl phenazinium methyl sulfate (PMS). Water soluble tetrazolium
generation 1 (WST-1) reduction is another tool that was used to investigate and measure
the NQO1 activity in myelin membrane [80]. The WST-1 carries multiple sulfonate
groups that confer the overall negative charge to WST-1 and prevent its transport across
the membrane [80, 94]. The reduced WST-1 (formazan) shows maximum absorption at
438nm. The NADH-dependent reduction of PMS is catalyzed by NQO1 then the reduced
PMS is recycled with the tetrazolium to the formazan (see Fig 4.10).
The effect of dicoumarol on PMS-mediated WST-1 reduction was determined in
the myelin (see Fig 4.11). No inhibition was observed for dicoumarol concentrations up
to the 100µM, thus again indicating NQO1 may not be the enzyme responsible for this
catalysis.
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NQO1

Fig 4.10: Modified mechanism of reduction of WST-1 by intermediate electron carrier
PMS. The intermediate electron carrier itself oxidises. Modified from reference [94].

Fig 4.11: Attempted inhibition of WST-1 reductase activity by dicoumarol. Myelin
(10µg) was assayed with 300µM WST and various concentrations (0, 10, 20, 50, 100µM) of
dicoumarol. NADH (250µM) was used as an electron donor. Results were produced in

triplicate and corrected for non-enzymatic activity. The temperature was kept at 37°C and
measurements were taken at 438nm.

4.3.2 (C): DCPIP Reductase Activity
The activities of cytochrome c reduction via menadione and WST-1 reductase
were not inhibited by dicoumarol. To further investigate the putative NQO1 activity, the
substrate was changed to DCPIP. Although, DCPIP is a substrate for various enzymes, it
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is an excellent substrate with NAD(P)H for measuring NQO1 activity [95]. The standard
reduction potential is as follows:
DCPIP (ox) + 2e-

DCPIP (red)

220mV

and
Ubiquinone + 2H + + 2e-

H2O + ubiquinol

45mV

Due to the greater standard potential, E´°, DCPIP is a better electron acceptor than
ubiquinone or menadione [63].
Lee et al. determined the NQO1 activity as the NADH-dependent reduction of
DCPIP [81]. As DCPIP is reduced by enzyme, the concentration of oxidized form
increased at 600nm [81]. The enzyme catalyzed reaction is shown for DCPIP reduction
with NADH as the hydride donor.

NQO1
H+ + 2eNAD+

NADH

Reduced form of DCPIP

Oxidized form of DCPIP

Fig 4.12: Reduction of DCPIP by NQO1. The DCPIP oxidized form is reduced by
NQO1 via hydride transfer.

The transfer of electrons or reduction of substrate from electron donor (NADH) to
terminal acceptor (DCPIP or CoQ) is catalyzed by two electron transfers in a two step
reaction; first from NAD(P)H to FAD and then to the substrate (DCPIP or COQ). A
typical rate of reaction of DCPIP reductase is illustrated in Fig 4.13. The decrease in
absorbance over time in the sample can be seen due to the reduction of DCPIP.
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Fig 4.13: Typical reaction rate of NADH-dependent reduction of DCPIP in the myelin. The
sample contains myelin, whereas, the negative control contains no myelin and represents the nonenzymatic reduction.

Further characterization of the DCPIP reductase activity was completed with the
whole myelin. The activity of enzyme was measured in three regimes; dose response of
enzyme, substrate dose response, and inhibitor(s) dose response. For the steady-state
kinetics, the activity was determined with various concentrations of substrate and enzyme
(see Fig 4.14 and 4.15). The result of myelin-dose response showed that there is a direct
relation between absorbance and amount of protein, thus protein is present in active state.

Fig. 4.14: DCPIP reductase activity as a function of amount of myelin. DCPIP (50µM) was assayed
with various amounts of myelin (10, 20, 30, 40µg). To initiate the reaction, 250µM NADH was added.
Measurement was taken spectrophotometrically at 600nm at 37°C. Results are produced in duplicate
and corrected for background. The error bars are ±SE (standard error).
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A

B

Fig 4.15: NAD(P)H: DCPIP reductase activity as a function of DCPIP substrate: Panel (A):
Substrate dependent dose response curve generated on the basis of various substrate
concentrations 20, 50, 100, 200, 300, 400 and 500µM with 10µg protein, 25mM Tris buffer and
2.5mM NADH. Electron transfer was monitored at 37°C at 600nm for 5 minutes at the interval of
20 seconds. All results are produced in duplicate and corrected for background. The error bars are
±SE. t-test results indicate an statistical significance of more than 95% (**p=0.039) confidence in
decrease in enzyme activity between 400µM and 500µM substrate concentration. Panel B): Data
fitted with kinetic software (zunzun.com) to determine apparent KMand Vmax. . The curve was
generated by fitting the 2D Hills equation. Solid line represents the data while dashed line
represents the 95% confidence of interval.
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The curve of the DCPIP substrate dependent enzyme activity is sigmoidal. A
sigmoidal curve suggests that the enzyme is allosteric in nature. The substrate inhibition
can be seen at the highest concentration of DCPIP. This finding is in strong agreement
with a study by Gustafson et al. which showed the inhibition of purified NQO1 activity
with DCPIP substrate at 300µM [96]. The substrate-based inhibition is considered as
physiological phenomenon not a pathological phenomenon. This phenomenon is
demonstrated by almost 20% of the enzymes, out of which, 90% were allosteric enzymes
[97]. Allosteric enzymes have two binding sites, one catalytic binding site, and another
non-catalytic or allosteric binding site. In the non-catalytic site the second substrate binds
and acts as an allostetric inhibitor by changing the conformation of the enzyme. As a
consequence of this conformational change the enzyme can no longer bind to the substrate
[97]. The mechanism is shown in Fig 4.16.

E+S

K1

E∙S

k2

E+P

+
KN
k3
S∙E∙S

E+S+P

Fig 4.16 Mechanism of substrate-based inhibition of allosteric enzyme. Two molecules
of substrate bind to the enzyme at a time at high concentration and inhibits enzyme activity. K1,
k2, KN and k3 are the dissociation constants.

Furthermore, the DCPIP reductase activity is due to the enzyme that can use more
than one substrate and have ping-pong mechanism. The enzyme that is using the DCPIP
substrate does not follow the Michaelis Menten model. Using kinetic software, the kinetic
parameters, Vmax and K0.5 were determined as 7.83 x10-5 µM/min and 251 µM,
respectively. Cytosolic NQO1 is NADPH dependent protein but it can use both the
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electron donors; NADH and NADPH, with same Vmax value, but the KM for NADH is
twice as that of NADPH [69, 77]. The dose response of electron donor NADH/ NADPH
was determined in Fig 4.17. The estimated values of Vmax and KM for NADPH were
determined as 6.86 x 10-5 µM/ min and 210 µM, respectively. In addition, the Vmax and KM
values for NADH were estimated 6.54 x 10-5µM/ min and 54.7µM, respectively. The KM
value of NADPH is almost more than thrice as that of NADH, which shows that enzyme
that is using DCPIP has NADH preference, contrary to NQO1, which has NADPH
preference in several cells types.

Fig 4.17: NADH: DCPIP reductase activity as a function of electron donor concentration.
Both assays used the 25mM Tris buffer, 10µg myelin, 100µM DCPIP, various concentrations
of NADH (0, 100, 200, 400, 500 and 600µM) and various concentrations of NADPH (0, 100,
200, 400, 500 and 600 µM). Measurement was taken at 600nm at 37°C. Results were produced
in triplicate and corrected for non-enzymatic activity. The error bars are ±SE. t-test results
indicate a statistical significance of more than 95%, with *p = 0.172 for NADH and **p =
0.312 for NADPH, respectively, between 500µM and 600µM electron donor concentration.

Jaiswal et al. illustrated that mNQO utilizes NADH as an electron donor with
three times greater affinity than NADPH [88]. In our findings, KM value of NADPH is
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more than three times greater than the NADH (Fig 4.17) and thus, the enzyme shows the
same greater affinity for NADH as with the mNQO. On the basis of KM value,
insensitivity to dicoumarol and molecular size, it can be speculated that DCPIP reductase
activity might be due to mNQO but not due to NQO1.
Specifically, the enzyme assays are validated when a potent inhibitor abolishes
the activity. The myelin samples were exposed to progressive increasing concentration of
dicoumarol. To determine the inhibitory effect of dicoumarol, enzymes in the myelin
were subjected to increasing concentration of dicoumarol (dissolved in DMSO or in 0.1N
NaOH). Results are shown in Fig 4.18 (A & B), respectively. As FAD is an important
component of electron transfer system in NQO1. To inhibit the activity of DCPIP,
enzyme assay was supplemented with FAD and dicoumarol (Fig 4.18C). Although the
FAD group is tightly associated with flavoenzymes, the supplementation was completed
in case some loss occurred with the isolation or treatment of the myelin.
A myelin sample without inhibitor was used as a control and considered as having
100% oxidoreductase activity (in this case, NADH: DCPIP reductase). Dicoumarol in
both solvents, DMSO and NaOH, did not show inhibitory effect on DCPIP reductase
activity (Fig 4.18 A & B). Moreover, addition of FAD with dicoumarol showed that
DCPIP reductase activity is also insensitive to its addition.
All NQO1 enzymes catalyze the two electron reduction reactions. Dicoumarol
binds to the each catalytic site and the interaction is facilitated by FAD. Like the NADH,
the plane of dicoumarol stacks parallel to the isoalloxazine ring of FAD at a distance of
4Å [71]. The coumarin ring of dicoumarol makes a hydrogen bond with His161. The
schematic of NQO1 interaction is shown in Fig 4.19 [71].
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A

B

C

Fig 4.18: Attempted inhibition of DCPIP reductase activity by dicoumarol. The reaction
rate of 10µg myelin was assayed with 50mM Tris/HCl buffer, in the presence of 50µM DCPIP
substrate, 200µM NADH and various concentrations of inhibitors. Activity was measured at
600nm and at 37°C. Results were corrected for non-enzymatic activity and produced in
duplicate Panel (A) Reductase activitywith dicoumarol in DMSO with 0, 10, 25, 50, 75, 100,
250, 500µM. Panel (B) dicoumarol in 0.1N NaOH with 0, 10, 20, 30, 50µM. Panel (C) 5µM
FAD with 0, 20, 50µM dicoumarol. The error bars are ±SE.
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Fig 4.19: Schematic of dicoumarol binding with human NQO1 active site. Figure taken
from reference [71].

Using dicoumarol as an inhibitor has two disadvantages: first is the lack of
specificity and second is its competitive mechanism of inhibition [98]. The concentration
of dicoumarol required to inhibit the DT-diaphorase activity varies with quinone acceptor,
which may lead to false conclusions of either involvement or estimation of NQO1 [99].
The mechanism-based inhibitor, ES936, is a better inhibitor of NQO1 rather than
dicoumarol. It is non-competitive inhibitor and only 100nM can inhibits more than 95%
NQO1 activity in 30 minutes [98].
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As DCPIP reductase activity is not inhibited by dicoumarol, it can be concluded
that it is not the NQO1 that is catalyzing the reaction. Then what enzyme(s) are
responsible for the DCPIP reductase activity? The DCPIP reductase activity was
examined through various oxidoreductase inhibitors due to utilization of DCPIP substrate
by several other enzymes. The inhibitory effects of DPI, pHMB, choloramphenicol,
rotenone, KCN and DMSO were determined (Fig 4.20 A-F).
High concentrations of DPI (500µM) did not inhibit the activity of DCPIP
reductase in myelin (Fig 4.20 A). Studies have shown that DPI does not inhibit the
activities of various quinone reductases, including NQO1 and some other flavoproteins
[100]. Thus, it is not surprising if DPI does not inhibit the DCPIP reductase activity.
Another explanation could be that the enzyme that is using the DCPIP is not a
flavoenzyme. DCPIP reductase activity was 50% inhibited by pHMB at 50µM (see Fig
4.20 B). Since pHMB is not a known inhibitor of NQO1-associated DCPIP reductase
activity it can be concluded that activity is associated with an enzymes, carrying a
cysteine residues or sulfhydryl group.
In order to preclude any associated mitochondrial activity, an inhibitor KCN, was
used. Potassium cyanide is a potent inhibitor of cellular respiration, and ultimately blocks
the oxidative phosphorylation. The DCPIP reductase activity showed the 50% inhibition
with 10µM KCN (Fig 4.20 C). Although is an potent inhibitor of cytochrome c oxidase
(complex IV of the mitochondrial electron transport chain), KCN is also a general
inhibitor of several heme

proteins, metallo enzymes, malic enzyme, creatine

phosphokinase and Cu, Zn superoxide dismutase [101, 102]. There is a possibility that
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activity of one of those enzymes is inhibited by KCN and can utilize DCPIP as a
substrate.
Chloramphenicol did not inhibit the DCPIP reductase activity (Fig 4.20D).
Chloramphenicol prevents protein chain elongation by inhibiting the peptidyl
transferase activity [103]. It specifically binds to the 50S ribosomal subunit, preventing
peptide bond formation. Usually it is used as an antibiotic and 10-20µM of
chloramphenicol inhibits 85% activity of the peptidyl transferase [103]. The result
confirmed that DCPIP is not utilized by an enzyme involved in protein synthesis.
As well, DCPIP reductase activity was not inhibited by rotenone (Fig 4.20 E).
Rotenone is a specific inhibitor of mitochondrial complex I. It inhibits the electron
transfer from iron-sulfur center to ubiquinone and eventually inhibits the ATP synthesis.
Almost 10pM of rotenone inhibits 50% of the complex I activity [104], unlike our
finding, where 500µM of rotenone did not inhibit the activity. It can be concluded that
the activity what we find is distinct from mitochondrial complex I activity.
Lastly, about 80% of the DCPIP reductase activity is inhibited by 17.5% (v/v)
DMSO (Fig 4.20 F). DMSO is a polar organic solvent and widely used in biology as a
differentiation inducer, and it also apprehends the growth of cells at G1 and M phase
[105]. DMSO enhances the permeability of the membranes by forming a pore, loosening
the structure or by collapsing the lipid bilayer in cholesterol-rich domain [106].
Moreover, in DMSO-dependent assays, its volume is typically kept as low as 0.1-5 %
(v/v) [106] and in our experiment, we use 2.5-17% DMSO. Most likely the inhibition by
DMSO is due to protein denaturation.
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Fig 4.20: Attempted inhibition of DCPIP reductase activity with different inhibitors: The
reaction rate of 10µg myelin was assayed with 50mM Tris/HCl buffer, in the presence of 50µM
DCPIP substrate, 200µM NADH and various concentrations of inhibitors. Panel (A): With DPI
at 0, 10, 100, 500µM. Panel (B): with 0, 1, 5, 10, 50, 100µM of pHMB. Panel (C): With KCN
at 0, 3, 5, 10, 50µM. Panel (D): With chloramphenicol at 0, 50, 100, 200, 400, 500µM. Panel
(E): With rotenone at 0, 20, 50, 100, 500µM. Panel (F): With DMSO at 2.5, 5.0, 7.5, 10.0,
17.5% (v/v). Activity was measured at 600nm and at 37 °C. Results were corrected for nonenzymatic activity and produced in duplicate. The error bars are ±SE and 95% CI was
established. The p values in Panel (F) are as follows: *p= 0.088, **p = 0.0806.

Fiore et al. described this denaturation activity as NADH-dependent DCPIP
reductase activity [105]. In addition, DMSO was considered as a potent inhibitor of
cyclin-dependent kinases (CDKs). T h e CDKs are a family of protein kinases that play
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a role in cell cycle regulation. The CDKs are also involved in regulating and transcription
of mRNA and are also involved in neuronal cells differentiation [105].
Zurbriggen et al. discovered DCPIP reductase activity in the plasma membrane of
mouse neuroblastoma cell line NB41A3 [107]. The activity was not inhibited by
dicoumarol, antimycin or rotenone, but the activity was inhibited by treating the cells
with DMSO [107]. Furthermore, the same group concluded that DCPIP reductase activity
is due to the unnamed enzyme which is similar to glyceraldehyde 3-phosphate
dehydrogenase (GAP). There might be a possibility that activity is solely due to isozyme
of GAP or could be a combination of two or more enzymes.
Several inhibitors were used to inhibit the NQO1 associated DCPIP reductase
activity, some of them (KCN, pHMB and DMSO) partially inhibited the activity and
some of them did not inhibit the activity (dicoumrol, rotenone, chloramphenicol). But our
major focus was the dicoumarol-dependent inhibition of

DCPIP reductase activity,

which was not achieved due to the non-functionality of the enzyme. There could be a
possibility that a novel isoform of NQO1, which is resistant to dicoumarol, is present.

4.4 Conclusions
In this study, the putative NQO1 presence in myelin membrane was investigated.
Western blotting and immunohistochemistry of NQO1 detected the enzyme in myelin
membrane. Furthermore, current study showed that NQO1 is present in a truncated form
which may not been responsible for the observed dicoumarol-insensitive DCPIP
reductase activity. Studies showed that NQO1 expression is tissue specific, ubiquitious,
tightly controlled by a gene and highly inducible. Previous studies showed that if NQO1
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is overexpressed, the cell becomes death resistant; this occurs in cancer cells. Several
xenobiotics, aging and oxidative stress can modulate its expression. Furthermore, if
enzyme is not required, it undergoes the posttranslational modification and degraded by
proteosomal attack.
The equivalence of the three possible methods for measuring NQO1 activity;
NADH-dependent cytochrome c reduction via menadione, DCPIP reduction and WST-1
reduction into formazan was assessed in myelin samples. The activity of NQO1 was
quantified by the use of the potent inhibitor dicoumarol. Several other inhibitors
including DPI, pHMB, and rotonone were used in an attemplt to inhibit the activity. DPI
reduced the 20% activity of menadione-mediated cytochrome c reductase [93, 108]. With
the DCPIP reductase assay, DPI did not inhibit any of the activity. Menadione-mediated
cytochrome c reductase activity was almost 35% inhibited by 50µM dicoumarol;
however, the DCPIP reductase activity was insensitive to dicoumarol. Overall, the level
of dicoumarol inhibition is far away from literature values for NQO1, where picomoles of
dicoumarol completely inhibit the activity. It can be concluded that DCPIP reductase
activity may be due to the other oxidoreductases and dehydrogenases which are residing
in the myelin membrane. These enzymes can use the substrate DCPIP but they were
partially or fully insensitive to dicoumarol. Secondly, there is a possibility that any other
novel isoform of NQO1, resistant to dicoumarol is present in myelin such as mNQO. The
electron donor of NQO2 is NRH (dihydronicotinamide riboside) but it can utilize NADH
and NADPH, very poorly. Wu et al. estimated the K0.5 value of NQO2 in liver cell culture
as 252µM when it was using DCPIP as a substrate [109]. This value is very close to our
estimated value of K0.5 which is 251µM, whereas with NRH electron donor and DCPIP
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substrate the KM value of NQO2 is 30µM [109]. Furthermore, NQO2 is almost
insensitive to dicoumarol [109]. It can be speculated that DCPIP reductase activity may
be due to NQO2.
Purification and protein sequencing can give the insight into the truncated isoform
present in the myelin membrane. For future NQO1 investigations ES936 inhibitor should
be used instead of dicoumarol.
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Chapter 5
Comparison of Oxidoreductases in
Healthy and Diseased Myelin
In this chapter, the previously investigated enzymes, CB5R and NQO1 are
examined in a demyelinating mouse model. The demyelination process is associated with
a pathology called multiple sclerosis (MS), and most commonly diagnosed in young
adults. The ND4 spontaneously demyelinating mouse model with age-matched controls
was used in this study. Furthermore, the level of superoxide production was also
investigated in healthy and diseased mouse myelin.

5.1 Introduction
Multiple sclerosis (MS), also known as
disseminated

sclerosis

or

encephalomyelitis

disseminata, is considered to be an inflammatory
disease in which the insulating sheath, the myelin
membrane, in the brain and/or the spinal cord is
damaged. This process is called demyelination
[110]. Due to the damage of the myelin sheath and
the disruption of macromolecules, plaques in
white matter can be seen (see Fig 5.1)

Fig 5.1: MRI image of MS brain.
The white areas are lesions or
plaques. Fig adapted from reference
[111].

The symptoms of MS correlate with the affected region. Contrary to the PNS,
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in the CNS the repair mechanism of myelin is complex and limited since one
oligodendrocyte cell is myelinating more than one axons.
The actual cause of MS is unknown but it is believed that MS is a combination of
several genetic, infectious and environmental factors [111]. Some common signs and
symptoms among MS patients include a loss of sensitivity or changes in sensation such
as tingling, pins and needles or numbness, muscle weakness, very weak reflexes, muscle
spasms, or difficulty in moving; difficulties with coordination and balance (ataxia);
problems with speech or swallowing, visual problems such as; blurry vision or
peripheral vision loss, (snystagmus, optic neuritis or double vision), and fatigue [111].
On the basis of symptoms, MS can be categorized into four classes [112]. The
first class is the relapse-remitting MS (RRMS) in which the signs and symptoms are
characterized by random appearance of symptoms that can lasts from hours to months
but patient recovers over a period of time. This is the most common type of MS and
almost 80% patients show these sign and symptoms in the beginning. RRMS is
further divided into two subtypes: 1- Benign MS: In this subclass the recovery is
almost complete and only limited progression in disability even after 20 years is
observed. 2- Clinically isolated syndrome: In this subclass, the patients have an attack
which is suggestive of promising demyelination, but the symptoms are insufficient
[110]. The second class is the primary progressing MS (PPMS) in which the
improvement in disability is very minor. This class is more equally distributed in men
and women. Otherwise, in all other classes women are more prone to disease. The
third class is the secondary progressive MS (SPMS). In this type there is no defined
time between the periods of symptoms. The disability worsens with the each episode
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of attack. Lastly, progressive relapsing MS (PRMS) is the class of MS in which
patients have progressive neurological decline from the onset of the disease. This
class may result in complete disability [110].
Although, the mechanism of action of MS is unknown it is believed that body's own
immune system, T-cells, attacks the myelin membrane and destroys it. In normal
circumstances, the blood brain barrier (BBB) is impermeable to these cells, but in diseased
condition, the BBB becomes permeable and T-cells destroy the myelin sheath (see Fig 5.2
A & B). Recently, Wu, et al. discovered that kallikrein (KLKB), a serine protease and
modulator of the T-cell antigenic determinant, is robustly upregulated in the
demyelinating brain [113].

A

B

Fig 5.2: Basic structure of neurons with myelin sheath in health and disease. (A) Healthy
myelinated neuron. (B) Demyelination due to the attack of T-cells. Fig taken from reference
[110].

5.1.1 Model of Demyelination
As the MS disease is considered multifactoral, comprehensive animal model or
models are required for its study. The available demyelinating models include viralinduced

demyelinating

models,

immune-mediated
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demyelinated

models,

and

genetically-induced demyelinated models. Artificial chemical-induced demyelination
can be induced by the exposure to cuprizone, a copper chelator. In this research project,
a transgenic mouse model, ND4 mice, was used. In ND4 mouse model, PLP is down
regulated due to an over-expression of a deletion mutant of PLP (DM-20) [114]. There
are almost 70 copies of the transgene encoding for the DM-20 protein in ND4 mouse
[114]. The ND4 mouse is clinically healthy at 3 months of age and has minimal
inflammatory signs. Around 3 months of age, without the injection of a myelin-specific
antigen such as myelin basic protein, ND4 mice spontaneously undergo demyelination
[114]. It is therefore, one of the genetically modified animal models for the study of
demyelinating disease and offers intrinsic manifestations of MS symptoms without any
external injections. In the ND4 model, demyelination is asymptomatic at 3 months of age.
Typically, by 8-10 months mice showed tremors and unsteady gait and have 17% myelin
as compared to a normal mouse [114]. Moreover, the disrupted myelin can be seen at 8
months of age and myelin debris can be seen in astrocytes [114].

5.2 Material and Methods
For CB5R and NQO1 investigations, the materials and methodology is the same
as described in section 3.2 and 4.2, respectively.

5.2.1 Measurement of Superoxide Detection
Increased superoxide production is the hallmark of increased oxidative stress.
Superoxide detection was carried out using a WST-1 reduction assay, in diseased and
healthy myelin of the same age. The superoxide reduces WST-1 into formazan (equation
5.1).
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O2.- + WST-1

Formazan +

O2

(5.1)

The assay mixture contained 100mM potassium phosphate, 2mM EGTA buffer
(pH 7.0), various concentrations (20, 30, 40µg) of healthy and diseased myelin, 50µM
NADH, and to initiate the electron flow, 300µM WST-1 was added. The total volume per
sample was brought up to 200µl with the addition of phosphate buffer. The reduction of
WST-1 into formazan was monitored at 37°C for 15 minutes at kinetic interval of 30
seconds. The increase in absorbance at 438nm was monitored with an extinction
coefficient of 37.0 mM-1cm-1 for formazan.

5.3 Results and Discussion
5.3.1 Investigation of Cytochrome b5 Reductase Activities in Diseased
and Healthy Myelin
CB5R is an enzyme that has been found in myelin membrane (see chapter 3). To
investigate the CB5R activities in diseased myelin, two age groups of ND4 mouse model
were used. The 7.7 month old mice represent the age group before physical symptoms of
demyelination are apparent. whereas the 11.3 month ND4 mice have significant
symptoms of demyelination. The cytochrome c reductase activity was measured in both
age groups of diseased and healthy mouse myelin (see Fig 5.3). The kinetic parameters,
KM and Vmax, were not determined as the enzyme activities did not reach saturation
(plateau curve). Fig 5.3 A & B represent dose response of myelin in both age groups,
which illustrates that the reduction reaction is directly proportional to the amount of
protein added. Overall, healthy myelin showed a greater activity as compared to diseased
myelin on an the basis of equal amount of protein.
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A
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C

D

Fig 5.3: Age-matched comparison of cytochrome c reductase activity in healthy and
diseased myelin. Panel A and B represents activity as function of myelin protein with 100µM
cytochrome c for the two age groups. Panel C and D represents the activity as a function of
cytochrome c with 10µg for both ages. The reaction was initiated with 250µM NADH. All assays
were performed at 37°C in a total volume of 200µl per well. Measurement was taken at 550nm.
All error bars represent ±SE.

Interestingly, all of these activities are lower when were compared with the
activity of CB5R found in chapter 3, where the age of the mice were approximately 2
month and the enzyme activity of 20µg of myelin with 100µM of cytochrome c was
0.28µmol/min. When examining reductase activity in healthy mouse myelin, at 2, 7.7,
and 11.3 months of age, the findings suggests that CB5R activity fluctuates over the
lifespan. However, in healthy myelin from 7.7 to 11.3 months, the activity greatly
increases (p= 0.001). This same statistically significant trend is seen in the diseased
myelin, from 7.7 to 11.3 months (p= 0.032).

88

Table 5.1: Comparison of cytochrome c reductase activity with 20µg myelin and
100µM cytochrome c in healthy and diseased samples. Enzyme activity from healthy
and diseased myelin were calculated from the reaction rates in figure 5.3 A and B using
the extinction coefficient of 29.5mM-1cm-1for the reduced cytochrome c at 550nm.
Mice Age Diseased myelin activity
(Months)
(µmol/min)
7.7
0.132± (3.252E-06)
11.3
0.180±SD (9.899E-06)
P values
p = 0.032

Healthy myelin activity P values
(µmol/min)
0.165±SD (2.333E-05) p=0.324
0.205±SD (9.192E-06) p=0.016
p= 0.001

Another comparison was made between healthy and diseased myelin, this time
with 10µg myelin and 500µM cytochrome c is utilized (see table 5.2). In comparing the
Table 5.2: Comparison of cytochrome c reductase activity with 10µg myelin and
500µM cytochrome c in healthy and diseased samples. Enzyme activity from healthy
and diseased myelin were calculated from the reaction rates in figure 5.3 C and D using
the extinction co-efficient of 29.5mM-1cm-1 for the reduced cytochrome c at 550nm.
Mice Age
(Months)
7.7
11.3
p-value (age
comparison)

Diseased myelin activity
(µmol/min)
0.425±SD (7.990E-06)
0.456±SD (5.656E-06)

Healthy myelin activity
(µmol/min)
0.232±SD (7.778E-05)
0.687±SD (3.535E-06)

p = 0.024

p = 0.001

p- values
(D vs H)
p=0.010
p=0.008

enzyme activities with 500µM cytochrome c between the 7.7 and 11.3 months old
healthy mice, the activities were statistically greater in the myelin of the older mice
(p=0.001). When comparing activities between diseased and healthy myelin at the same
age, the younger mouse diseased myelin showed the greatest activity (p=0.01 and p=
0.008, respectively). However, the older mice, healthy mouse showed the greatest
activity. Interestingly, when these activities were compared with the activity of CB5R
found in chapter 3, where the age of the mice were approximately 2 months, the enzyme
activity of 10µg of myelin with 500µM of cytochrome c was 0.673µmol/min. However,
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again in the healthy myelin from 7.7 to 11.3 months there is greater activity (p= 0.001).
In diseased myelin there is increase in activity in older mice (p= 0.024).
Lastly, the pHMB-dependent inhibition of the enzyme activity demonstrated that
at 7.7 months of age the disease myelin cytochrome c reductase activity is more
susceptible to pHMB inhibition (see Fig 5.4). However, in the 11.3 months age group, the
pHMB inhibitory effect is almost the same in diseased and healthy myelin, as shown
statistically. In chapter 3, the 1µM of pHMB inhibited the 50% enzyme activity in myelin
from ~2 months old mice. This decreased effect of pHMB inhibition with age may be
related to an increased level of protein expression.
Several reactive oxygen species (ROS), such as superoxide radical (O2-.) and
hydrogen peroxide (H2O2), play a crucial role in cell signaling [115, 116]. These species
performed very vital functions for cells as phagocytosis, hormone synthesis and apoptosis
[117]. Various pathological conditions are associated with the increased oxidative stress
[115]. Oxidative stress is a condition in which level of ROS such as superoxide radical,
hydrogen peroxide and peroxynitrite are elevated. These elevated ROS can damage the
protein and lipids. Oxidative stress increases over a significant time period, and thus it is
an age-related phenomenon. In the aging process, ROS damage the mitochondrial DNA
(mDNA) and results in impaired mitochondrial function energy production and the
subsequent reliance on glycolysis. This results in the hyper-reactivity of t-PMET [118].
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Fig 5.4: The pHMB-mediated inhibition as a function of cytochrome c reductase activity.
The reaction was initiated with 250µM NADH, 10µg myelin, and 100µM of cytochrome c in the
presence or absence of 1µM pHMB. Measurement was taken at 550nm at 37°C. All error bars are
±SE. The t-test values, *p=0.083 and **p=0.294 are established at 95% CI.

In various cells NOX is responsible for producing superoxide [17]. In this study
the superoxide production was carried out in healthy and diseased myelin of the same age
to investigate the levels with the disease progression. To detect any measureable quantity
of superoxide, oxidation of WST-1 into formazan was followed at 438nm. This reaction
was NADH-dependent (see equation below).
NADH + 2O2

Enzyme

NAD+ + 2O2.-

Fig 5.5 shows that superoxide production has a direct relation with the amount of
protein.

The diseased myelin, as we hypothesized, showed the greater superoxide

production as compared to healthy myelin. Furthermore, both groups of protein showed a
plateau curve which may be due to the insufficient substrate. In all cells, generally,
superoxide dismutase (SOD) enzyme is responsible for dismutating the superoxide (O2.-)
into H2O2 and O2. But, at a threshold level of ROS, the SOD activity decreases and as a
consequence superoxide damages the macromolecules.
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Fig 5.5: Comparison of superoxide production rates in healthy and diseased myelin: Various
concentrations of 5.34 months old mouse myelin (20, 30, 40µg) were assayed with 300µM of
WST-1. To initiate the reaction 250µM of NADH was added. In each well, volume of reaction
mixture was made up to 200µl by adding 100mM potassium phosphate buffer with 2mM EGTA
buffer, pH 7.0. Measurements were taken at 438nm at 37°C. Results were produced in duplicates
and corrected for non-enzymatic activity. The error bars are ±SE.

Due to limited availability of related published literature it was not possible to
compare the activities of CB5R with different model systems. As mentioned earlier
recent research published in March 2014 showed that CB5R and NOS are associated
through the caveolin protein in lipid cholesterol-raft region [92]. Furthermore, CB5R
itself is involved in superoxide production and superoxide production increases with age
[115].
Previous studies discovered that CB5R also regulates the release of nitric oxide
[108, 119, 120]. In light of previous and current study scenarios it can be postulated that
modulation in CB5R activity may trigger the uncontrolled NO. production and release.
The NO. is the first known endogenous inhibitor of superoxide dismutase (SOD) and
.
competes for the availability of superoxide radical (O2 -) to form peroxynitrite (OONO-)

92

[121]. The OONO- is a very toxic species, and has the ability to damage the BBB [122].
The schematic of the CB5R-dependent BBB dysfunction is illustrated in Fig 5.6.

BBB Damage
SOD activity
OONO-

Disease

Higher O2.-

Healthy

Producing O2.-

Higher Activity
of CB5R

Uncontrolled NO.

Controlling NO.
CB5R normal
activity

Fig 5.6: Schematic of hypothesis of CB5R-induced BBB damage. In healthy cells CB5R
controls the release of nitric oxide and also a producer of superoxide radical. In diseased state
with the disruption of CB5R function, nitric oxide release is uncontrolled and superoxide
production may increase. It is hypothesized that the uncontrolled nitric oxide and superoxide
forms the peroxynitrite specie which is very harmful to the cells. Studies shows that peroxynitrite
can damage the blood brain barrier.

In neuronal cells the "L-shaped" calcium channels are present in close proximity to
CB5R within the lipid raft region [19]. These calcium channels are also found in
oligodendrocytes [123]. The calcium channels are also called sodium-calcium exchanger.
This exchanger is an antiporter membrane protein that removes calcium from the cells. It
removes a single calcium ion in exchange for the three sodium ions [124]. It can be
proposed that both of the isoforms of CB5R may regulate calcium homeostasis and influx of
Ca2+ into the cells by their association with Ca2+ channels. Previous studies also show that
calcium toxicity as one of the major cause of axonal degeneration [125].

In axonal

inflammation Na+ channels redistribution affects the Na+/Ca++ exchange and increases the
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calcium influx into the cells [125]. The high calcium level initiates the calcium-dependent
proteolytic degradation. Furthermore, excessive Ca++ entry releases the glutamate and this
glutamate and Ca++ harm the axon and cause degeneration. The schematic of the procedure
is shown in Fig 5.7.

Fig 5.7: Schematic of calcium induced toxicity and axonal degeneration. Two pathways for
axonal injury are shown. First pathway shown in red color, deals with the mitochondrial dysfunction.
Second pathway shown in blue, deals with the consequence of demyelination and calcium toxicity.
Oxidative stress redistributes the channel organization in the myelin membrane and as a consequence
energy depletes and excessive calcium enters the cells. This increase in calcium triggers the
glutamate release which is harmful to the cells. Fig adapted from reference [12].

5.3.2 Investigation of NQO1 in Healthy and Diseased Myelin
5.3.2.1 Immuno-Detection of NQO1 in Diseased and Healthy Myelin

NQO1 has been previously identified in the myelin membrane (see chapter 4),
but mainly in a truncated, non-functional form. Although various associated reductase
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activities were present, none were inhibited by dicoumarol, a NQO1 specific inhibitor.

150 kDa
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Truncated NQO1
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Fig 5.8: Western blot of NQO1 in diseased and healthy myelin. A 14% resolving gel
along with 4% stacking gel was prepared to examine the NQO1 expression level in diseased and
healthy myelin of different ages. A volume of 16µl of delipidated myelin (disease and healthy of
both age groups) (in final volume) with 5x sample loading buffer was loaded. Dual Colour
Precision Plus protein standard (5µl) in 1:10 dilution was also loaded with sample. The protein
on the gel were electrotransferred to a nitrocellulose membrane, which was incubated with
primary NQO1 antibody in a 1:1000 dilution for 4 hrs. Subsequently after washing, membrane
was incubated with secondary antibody anti-rabbit IgG in a 1:80,000 dilution for 30 minutes.
Image was taken with 4000 VersaDoc. Letter "D" represents diseased myelin, whereas "H"
represents healthy myelin.

Western blot analysis of NQO1 in diseased and healthy myelin was performed
between two age groups. In diseased myelin of both ages, NQO1 was detected at
~30kDa, whereas in the middle-aged healthy myelin (7.7 months) a truncated form was
detected, as previously observed in the young mice (~2 months) (see Fig 4.4 A).
Contrary to 7.7 months old healthy myelin, in 11.3 months old healthy mouse myelin,
only the full-length NQO1 was detectable. This might be due to the age of the mouse.
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The healthy mouse of 11.3 months has completed almost 65% of its life span and the
presence of full length NQO1 in myelin membrane may be related to the higher
oxidative stress levels found with aging. Aging is a biological process in which the free
radicals produced by metabolic processes damage the macromolecules of the cells. They
also damage the mitochondria and as a consequence the ratio of pyridine nucleotides,
NADH/NAD+ is disrupted [126]. To maintain the ratio of NADH/NAD+, t-PMET is
activated in an aged brain [118] (see further discussion in chapter 6).
Previous studies are in agreement with current results. They show that NQO1
accumulates in the aged brain, and in addition the age-related elevated level of NQO1
might be cellular protection mechanism [127]. Another theory postulates that as NQO1 is
involved in lipid metabolism [128] there is a possibility that it is involved in
myelinogenesis, and after birth its level gradually falls and it became inactive [86].
The NQO1 is highly inducible enzyme [82]. Generally, it is believed that the
expression of NQO1 is under the control of a promoter, called antioxidant response
element (ARE) [129, 130]. This factor is the adaptive mechanism of cell against
oxidative stress [131]. The ARE-related genes are involved in several functions of the
cell as a response to external stimulus such as glutathione regulation, catalase expression,
proteosomal degradation and redox status [132]. The Nrf2 is the key signaling protein,
that post-translationally regulates the ARE pathway. Under normal circumstances in
cytosol the Nrf2 is conjugated with kelch-like ECH-associated protein 1 (Keap1). Keap 1
protein initiates the ubiquitinal degradation of Nrf2. Nrf2 dissociates from Keap1 by two
ways: 1- directly by phosphorylation, 2- indirectly by

signal induction due to

endogenous or exogenous factors. After dissociation, Nrf2 binds to the promotor ARE
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sequence in the nucleus and activates the transcription of antioxidant elements such as
NQO1 and glutathione reductase ( see Fig 5.9) [84]. In addition, Hyun et al. describes
that two transcriptional factors, Nrf2, NF-ƘB and HSP70 have elevated levels in a
system with high oxidative stress [84].

Nrf2

Fig 5.9: Mechanism of activation of ARE pathway. The antioxidant responsive element
(ARE) is a regulatory element of genes encoding phase II detoxification enzymes and antioxidant
proteins, such as NQO1 and glutathione S-transferases. Interestingly, it has been reported that
Nrf2 regulates a wide array of ARE-driven genes in various cell types. The DNA binding
sequence of Nrf2 and ARE sequence are very similar, and many studies demonstrated that Nrf2
binds to the ARE sites leading to up-regulation of downstream genes. The function of Nrf2 and
its downstream target genes suggests that the Nrf2-ARE pathway is important in the cellular
antioxidant defense system. Fig adapted from reference [84].

The Ross group identified the NQO1 localization in the nucleus of several colon
and lung cancer cells using 3D-confocal microscopy [70]. The translocation of NQO1
proteins into the nucleus occurred through a nuclear pore complex [133]. The function of
the nuclear NQO1 is to protect the DNA from damage and its repair through activation
of Sirtuins 1 (SIRT1) and poly ADP-ribose polymerase (PARP) enzymes [61]. Further,
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David et al. describes the NQO1 presence in mitotic spindle as well as in centrosomes in
human pancreatic cancer cell [133]. Using the double-labeling immunostaining and
specific antibodies against NQO1 they discovered that NQO1 is attached to alphatubulin in the mitotic spindle fiber [133].
5.3.2.2 Measurement of DCPIP Reductase Activity in Healthy and Diseased Myelin

To further characterize the NQO1, the DCPIP reductase activity was compared in
diseased and healthy myelin in 7.7 months old mice (see Fig 5. 10). In both diseased and
healthy myelin the activity increased with the concentration of DCPIP substrate. The
DCPIP reductase activity was partially inhibited by dicoumarol in both groups. However,
the statistical analysis indicated that there is almost the same level of inhibition in both
groups. This partial inhibition (~40-45%) in older and diseased myelin is in contrast to
the lack of inhibition of the DCPIP reductase activity in myelin from young mice (see
chapter 4).

A

B

Fig 5.10: Comparison of DCPIP reductase activity in healthy and diseased myelin.
Panel (A): Reductase activity as a function of DCPIP substrate concentration. Myelin
(20µg) was assayed with various concentrations (10, 25, 100, 500µM) of DCPIP. The value of
*p= 0.356. Panel (B): Inhibition of reductase activity with dicoumarol. The activity was
measured with 20µg of protein and 50µM DCPIP in the presence of 50µM dicoumarol. The age
of the mouse was 7.7 months. The t-test value of *p=0.255 established at 95% CI. To initiate the
reaction 200µM of NADH was added and the final volume per well was 200µl. The
measurement was taken at 600nm at 37°C for 5 minutes. All error bars are ±SE.
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5.5 Conclusions
A preliminary study that compared the redox activities in age-matched healthy
and diseased myelin was conducted. On the basis of current research findings it can be
concluded that CB5R activity increases overall with age. As well, in healthy myelin the
activity of CB5R was enhanced relative to age-matched diseased myelin. CB5R may be
responsible for superoxide production, and high levels of oxidative stress occur in aging
and in disease processes. It is hypothesized that superoxide spontaneously reacts with
nitric oxide to form the reactive peroxynitrite ion that confers the permeability to BBB.
Moreover, it could be one of the factors in etiology of MS.
The NQO1 was detected in the full length form at 30kDa by Western blot analysis
in the diseased myelin from 7.7 and 11.3 months old mice. Only in the older healthy
myelin (11.3 months) the full length form was detected; in the middle-aged myelin (7.7
months) a truncated form (~13 kDa) of the enzyme was found. Diseased state and age,
correlate with the presence of full length NQO1. Moreover, the expression of NQO1 is
under the control of the ARE factor, and can be induced by pathology and aging.
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Chapter 6
Summary, Conclusions and Future
Directions
This dissertation has utilized various kinetic assays and immunodetection
techniques to identify the oxidoreductases in the CNS myelin. The conclusions based on
the research work performed are drawn in this chapter. The identified proteins are
compared on the basis of activities, structure and function. Moreover, a number of future
avenues that can be explored to enhance present research are highlighted.

6.1 Summary and Conclusions
A study on the characterization of t-PMET in the myelin membrane was
conducted. On the basis of current research, specific activities of all oxidoreductase are
calculated in Table 6.1
Table 6.1: Specific activities of oxidoreductases with various substrates.
Oxidoreductase activity

Specific activity (nmol/min/mg)

NADH: cytochrome c reductase activity

3.401

NADH: DCPIP reductase activity

0.891

NADPH: DCPIP reductase activity

0.208

NADH: menadione reductase activity (with

0.871

cytochrome c)
NADH: PMS reductase activity (with WST-1)

0.633

NADH-dependent WST-1 reduction

0.499
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The specific activity of NADH: cytochrome c reductase (3.401nmol/min/mg) is
greater in all above calculated oxidoreductase activities. The enzymes activities of NADH:
DCPIP reductase and NADH: menadione reductase, 0.891 and 0.871 nm/min/mg
respectively, are almost the same. In addition, NADH is the preferred electron donor for the
enzyme which uses DCPIP as a substrate. Furthermore, NADPH: DCPIP reductase activity
is lowest (0.208nm/min/mg) of all measured oxidoreductase activities.
Current study discovered that CB5R, a member of t-PMET system, is expressed
in the mouse myelin membrane. The activity of CB5R was measured through cytochrome
c reductase and was inhibited by pHMB, a specific inhibitor of CB5R. Furthermore, the
CB5R has estimated Vmax and KM values as 6.58 x 10-5 µM/min and 151µM,
respectively. The sulfhydryl agent pHMB, inhibited almost ~90% activity at a
concentration of 10µM. Differential detergent fractionation of myelin suggests that the
CB5R may be localized in the lipid raft microdomains of myelin membrane.
Furthermore, two bands detected by Western blotting may indicate the myristoylated and
non-myristoylated forms of the protein.
The CB5R activity was also investigated in a diseased myelin model and
compared to control healthy mouse myelin. The results illustrate the variation in activity
over the normal growth period. In the healthy control, the 2 months old mouse myelin
showed greater activity than the 7.7 months old mouse myelin; however, the greatest
activity was in the 11.3 month old. Overall, the activity of CB5R increased with the age
in both the myelinated (healthy) and demyelinated (diseased) state. Some recent studies
found that the crucial roles affiliated to CB5R are superoxide production, controlling of
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NO. levels and the formation of peroxynitrite [134] . Furthermore, from previous studies
it can be speculated that calcium toxicity is related to CB5R [12].
CB5R performs important cellular functions such as CoQ reduction, cholesterol
synthesis, and fatty acid chain elongation. It is assumed that CB5R may perform similar
functions in the myelin sheath. The major function of the oxidoreductases and
specifically, CB5R, is to regenerate the NAD+ and replenish the pool of pyridine
nucleotides, NAD+/NADH.
Immunodetection of NQO1 confirmed its presence in myelin membrane. Differential
detergent fractionation of myelin and Western blot analysis indicates that NQO1 may be
localized in the lipid raft microdomain of myelin membrane. In addition, Western blot
analysis confirmed that NQO1 is present in truncated form. This truncated form could be
mNQO-like form or degraded product of NQO1. The other protein band appeared with
molecular weight ~27kDa could be the NQO2 or a novel NQO1 isoform. In diseased myelin,
due to high oxidative stress, the NQO1 expression level was elevated and band appeared at
30kDa (full length) instead of ~13kDa. The fluctuation in the expression level may suggest
its role in myelinogenesis, aging, and disease. Thus, it can be concluded that NQO1
associated activity is present in the myelin membrane but at a different level depending on
cell function and physiological demands. Furthermore, the NQO1 gene is under the control
of ARE promoter, which activates due to the effect of xenobiotics, oxidants, heavy metals
and ionizing radiation.
Activity of NQO1 was measured through three associated activities: menadionemediated cytochrome c reductase, PMS-mediated WST-1 reductase activity and DCPIP
reductase activity. Kinetic analysis of the DCPIP reductase activity illustrated that the
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enzyme is allosteric in nature. In addition, it is insensitive to dicoumarol, a potent inhibitor of
NQO1, but due to several disadvantages of dicoumarol,

such as lack of specificity,

dicoumarol should be replaced by ES936 in future. The ES936 is more specific and
mechanism-based inhibitor of NQO1. The DCPIP reductase activity was inhibited by
DMSO, which has been previously used as G1 and M phase inhibitor in cell cultures. With
lipid bilayers, DMSO can form pores and denature the protein when these proteins are
present in cholesterol-rich domains [106]. As well enzymatic activity can be inhibited by
DMSO due to unfolding and denaturation of protein. The reductase measured activities could
be due to dehydrogenases or may be due to cyclin-dependent protein kinases or GAP.
Moreover, in diseased myelin, DCPIP reductase activity was enhanced as compared to the
healthy myelin of the same age, which shows its involvement in disease implication.
The pyridine nucleotide synthesis or ratio reduces due to the alteration of
intracellular status. The reduced synthesis of pyridine nucleotide is compensated by
reduced metabolism of glucose and fatty acids. The t-PMET may be responsible for
maintaining NAD+/NADH ratios in the myelin membrane. Therefore, in the cells where
mitochondria is dysfunctional, t-PMET is elevated [61]. One of the functions of
plasmalemellar CB5R enzyme is to produce the NAD+ (a primary marker of intracellular
status). As NADH-dependent enzyme, lactate dehydrogenase (LDH), is responsible for
converting the pyruvate into lactate, along with lactate it also regenerates the NAD+. In
myelin membrane, LDH is present, but by the 120th day of birth in mouse, its activity is
less than 8% [135]. Thus, t-PMET can regenerate NAD+. This NAD+ is utilized by other
enzymes including sirtuin1 (SIRT 1) and sirtuin2 (SIRT 2) [136]. Sirtuins, which are
localized in the plasma membrane and also found in myelin membrane, are NAD+
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dependent deacetylases [136]. Sirtuins expression in the myelin membrane is PLP and
DM-20 dependent [61, 136]. Both SIRT1 and SIRT2 proteins perform vital cell functions
such as cell cycle regulation, differentiation, chromatin stabilization, deacetylation, and
PLP-dependent neuroprotection [136]. The most important role of SIRT2 is the
deacetylation of MAG, an integral membrane protein found on the myelin layer closes to
the axon. MAG protein inhibits the regeneration of neurons in the CNS [137, 138]. The
level of NAD+/NADH is responsible for sirtuins activation and deactivation. During
aging NAD+/NADH ratios are altered, and thus the activity of sirtuin is modulated. In
plasma membrane, NAD+ which is utilized by sirtuins, is regenerated by CB5R, NQO1,
and other oxidoreductases (see Fig 6.1).

SIRT1/SIRT2 Enzyme

NAD+

NADH

Oxidoreductase
CB5R and/or NQO1

Fig 6.1: Regulatory mechanism of sirt1 by CB5R and other oxidoreductases in plasma
membrane. SIRT1 maintains the respiration, deacetylation and cytosolic NAD+/NADH
ratios.

NQO1 is involved in several important functions such as chemo protection,
protection of p53 gene and reduction of CoQ. The reduction of CoQ by NQO1 without
forming the semiquinone is very crucial for cell survival. CoQ is very important as it
electronically links the inner environment of the cell to the external environment of the cell.
Within lipid bilayer of the plasma membrane and the myelin membranes, CoQ scavenges
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superoxide radical with or without α-tocopherol by breaking the free radical chain reaction
[28]. Reduced CoQ is also responsible for avoiding the apoptosis initiated by ceramide
signaling. The ratio of CoQ/CoQH2 is the modulator of sphingomyelinase [139].
Sphingomyelin, a very common and important phospholipid, is present in plasma
membrane. This lipid is activated by an enzyme sphingomyelinase and has the ability to
induce the apoptosis by initiating the ceramide signaling. CoQH2 inhibits the activation
of spingomyelinase and protect the cell from unnecessary apoptotic signaling. The
oxidized form of CoQ can accumulate the ceramide molecules which may lead to form
ceramide-enriched platform. This platform can further initiate the death receptors to
cluster in the membrane and can transmit an efficient death signal. The Fas receptors are
also called death receptors, and are present on the surface of cells that leads to
programmed cell death (apoptosis). It is one of two apoptosis pathways, the other being
the mitochondrial pathway. Death receptor ligands characteristically initiate signaling via
receptor oligomerization, which in turn results in the recruitment of specialized adaptor
proteins and activation of caspase cascades [140, 141].The mechanism is shown in the
Fig 6.2.
In short, the major function of both identified enzymes is to maintain the
NAD+/NADH ratios and to reduce the CoQ in myelin membrane. CB5R accomplish this
task by one electron reductions while NQO1 reduces the CoQ by two electrons reduction
and avoides the formation of ROS. The two electron reduction

reaction in plasma

membrane is also performed by GSH and NQO2 [142]. These two proteins perform almost
the same function; it would be interesting to differentiate them on the basis of their
similarities and differences (see Table 6.2).
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Fig 6.2: Archetecture of ceramide signaling generated by NQO1/CoQ.The alteration of
CoQ/CoQH2 ratios can trigger the apoptosis. Once sphingomyelinase activated it can induce the
death signal. Fig adapted from reference [139].

Table 6.2: Similarities and differences between CB5R and NQO1. The comparison is
done on the basis of structure, function, and catalytic mode.
Based On
Sub-cellular
localization

Similarities
Both
proteins
have
multiple locations in the
cell.

Structure

Both proteins have two
lobes and αβα motifs.

Prosthetic
group

Both protein utilizes FAD
as a prosthetic group.

Catalytic
mode
of
action

Both reduce CoQ.

Enzyme
nature

Both are oxidoreductases.

Differences
• CB5R is present in endoplasmic
reticulum, Golgi bodies, mitochondria
and plasma membrane.
• NQO1 is present in cytosol, plasma
membrane and nucleus.
• In CB5R both lobes are connected by a
short hinge but it is monomeric
protein.
• NQO1 is homodimeric protein.
• There is only one FAD group in
CB5R.
• Whereas in NQO1, there is one FAD
per monomer.
• CB5R catalysis the one electron
reduction
• NQO1 catalysis the two electron
reduction
• CB5R exhibits the typical "lock and
key" model of enzyme, hence follows
the Michaelis Menten curve.
• NQO1 exhibits the "induced fit" model
and allosteric in nature.
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In conclusion, taken together, the hypothesis of current research that "t-PMET
assisting the myelin membrane" is supported as two components of t-PMET, CB5R and
NQO1, were found in the myelin membrane, and another component, VDAC, was
previously studied in our lab. The major function of both the identified proteins, CB5R and
NQO1, is the regeneration of NAD+ with the CoQ reduction by one and two electrons,
respectively. Fig 6.3 illustrates the presence and function of CB5R and NQO1 in t-PMET.

1e-

2e-

Fig 6.3: CB5R and NQO1 in t-PMET. CB5R catalysis one electron reduction while
NQO1 catalysis two electron reduction of CoQ. Figure modified from reference [51].

In light of current research findings and previous studies, it can be concluded that the
role of both identified proteins in disease state are interlinked. The overall scenario of both
proteins in oxidative stress is depicted in Fig 6.4.
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BBB Damage
Due to ROS
NOS

NO.

O2.-

ONOO

SOD

-

Oxidative
Stress ROS/ O2.-

ROS
NQO1

CB5R

Fig 6.4: Role of NQO1 and CB5R in demyelination. Besides NOX, CB5R is another
source of superoxide production and it also controls the release of NO. When function of CB5R
is disrupted regardless of the cause, NO release becomes uncontrolled and it can form the
peroxynitrite species, studies shows that it has the ability to damage the BBB, the barrier
becomes permeable to T-cells, which destroys the myelin sheath. Alternatively, SOD and NQO1
try to dismutase and scavenge the superoxide respectively. But at threshold level oxidative stress
is so high that NQO1 and SOD cannot accommodate it and result is the diseased condition or
demyelination.

6.2 Future Directions
On the basis of this work, we have identified the following aspects that presented
a good avenue for future investigation.

6.2.1 Bioanalytic Separation of Oxidoreductase Activities and the
Proteomic Identification
Enzyme activity assay and western blot analysis confirm the presence of
cytochrome b5 reductase and NQO1 in myelin membrane. It would be beneficial to
separate and purify the enzyme responsible for these activities. For this purpose, a dyeaffinity chromatography technique can be employed. Affinity chromatography is a
method of separating biochemical mixtures based on a highly specific interaction such as
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that between antigen and antibody, enzyme and substrate, or receptor and ligand. Affinity
chromatography can be used to purify and concentrate a substance [143].
Blue-sepharose affinity chromatography can be used for enrichment of
oxidoreductases from the myelin membrane. Blue-sepharose affinity chromatography
uses cibacron blue as the ligand linked to a cellulose-meshwork, such as sepharose.
Cibacron blue is a polycyclic dye resembling the structure of NADH. It is thought that
resemblance with NADH allows cytochrome b5 reductase and NQO1 to bind with
cibacron blue. Since the blue chromophore contains both amino and sulfonate groups, the
so called “non-specific” ion-exchange effects would also be expected [144].
Some other future directions related directly or indirectly to current research are
as follows:
•

Proteomic analysis of all oxidoreductases in the myelin membrane

•

Protein sequencing in diseased and healthy myelin should be done to detect any
mutation in the enzyme.

•

Instead of dicoumarol, inhibitor ES936 should be used for future NQO1
investigations.

•

MS is a disease which is prevalent in the countries where the albedo coefficient of
UV rays is very high. The effect of UV light on myelin membrane could reveal
some interesting facts.

• Role of CB5R in calcium and peroxynitrite toxicity should be unmask.
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